Document:

Exhibit 10.57
​
Confidential
Execution Version
​
*Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
​
AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT
​
This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of December 1, 2020 (the “Amendment Effective Date”), by and between UNIQURE BIOPHARMA B.V., a corporation organized under the laws of the Netherlands, having its principal place of business at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 430 E. 29 Street, 14 Floor, New York, New York, USA 10016.  UNIQURE N.V. is a party to this Agreement solely for purposes of Section 2.  uniQure and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
​
RECITALS
A.uniQure and BMS are parties to that certain Collaboration and License Agreement, dated April 6, 2015 (the “Agreement”), pursuant to which the Parties are collaborating to discover and develop gene therapy products for the treatment of cardiovascular diseases.
​
B.BMS and uniQure N.V., an Affiliate of uniQure, have also entered into that certain Investor Agreement (the “Investor Agreement”), that certain Share Subscription Agreement (the “Subscription Agreement”), that certain Seventh Collaboration Warrant Agreement, and that certain Tenth Collaboration Warrant Agreement (collectively, the “Warrant Agreements”), each one dated April 6, 2015.
C.The Parties now wish to concurrently amend the Agreement, in accordance with Section 17.1 thereof, to limit the number of Collaboration Targets and to modify the indication exclusivity provisions and certain financial terms, among other changes, and to terminate the Warrant Agreements.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Amendment, uniQure and BMS, intending to be legally bound, agree as follows.
	1.
	DEFINITIONS

Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings such terms are given in the Agreement
	2.
	TERMINATION OF WARRANT AGREEMENTS; CHANGE OF CONTROL PAYMENT

2.1Warrant Agreements.  BMS and uniQure N.V. hereby agree that on the Amendment Effective Date, each of the Warrant Agreements shall terminate and be of no further force and effect, without any exercise by BMS of its right to subscribe for and acquire from uniQure N.V. the Warrant Shares (as defined thereunder).
​
​

​
2.2Payment upon Change of Control of uniQure.  Subject to the provisions of this Section 2.2, substantially simultaneously with the consummation of the first Change of Control Transaction of uniQure that occurs prior to the earlier of (i) [*] anniversary of the Amendment Effective Date and (ii) BMS’ delivery of a Target Cessation Notice for all four (4) Collaboration Targets, uniQure (or its Third Party acquirer) shall pay to BMS in Dollars via electronic funds transfer to an account designated by BMS a one-time, non-refundable, non-creditable cash payment (the “Change of Control Payment”) of seventy million dollars ($70,000,000), provided that (x) if seventy million dollars ($70,000,000) is greater than five percent (5.0%) of the Net Proceeds from such Change of Control Transaction, the Change of Control Payment shall be an amount equal to five percent (5.0%) of such Net Proceeds, and (y) if seventy million dollars ($70,000,000) is less than one percent (1.0%) of such Net Proceeds, the Change of Control Payment shall be an amount equal to one percent (1.0%) of such Net Proceeds.  For the avoidance of doubt, the sale or transfer of uniQure N.V. constitutes a Change of Control Transaction as set forth in subsection (3) of the definition of Change of Control Transaction (set forth in the Agreement).  [*]. Net Proceeds shall be calculated as set forth in Schedule 2.2.  For clarity, (a) the foregoing payment shall apply only to the first Change of Control Transaction of uniQure and not to any subsequent Change of Control Transaction and (b) the foregoing payment shall be in addition to any amounts paid or payable to BMS in connection with a Change of Control Transaction in respect of any equity securities of uniQure (or any of its Affiliates) held by BMS at such time or in respect of any other agreement, understanding or arrangement between uniQure and BMS, or their respective Affiliates, at such time.
2.3Target Cessation Notice.  With respect to each Collaboration Target, BMS shall, in good faith, notify uniQure in writing promptly following BMS’ termination of all research, Development and Commercialization (if applicable) of all Target Therapeutics for such Collaboration Target (such notice, a “Target Cessation Notice”).
	3.
	AMENDMENT OF THE AGREEMENT

3.1Research Program.  The Parties agree that, notwithstanding anything in the Agreement to the contrary:
(a)the Research Term expired at the end of the Initial Research Term on May 21, 2019;
(b)notwithstanding such expiration of the Research Term, the Parties shall continue to conduct the Research Program under the Research Plan in accordance with the terms of the Agreement, until the earlier of  [*];
(c)from and after the Amendment Effective Date, there shall be no more than four (4) Collaboration Targets;
(d)as of the Amendment Effective Date, the Collaboration Targets and the Exclusive Indications that BMS is pursuing are those set forth in Schedule 3.1 (such Targets, the “Existing Collaboration Targets”), and all of the Existing Collaboration Targets are BMS Proprietary Targets;
(e)as of the Amendment Effective Date, there are no Reserved Targets and no Targets in which BMS is potentially interested that are subject to the terms of Section 3.4(d) of the Agreement;
​

2

​
(f)from and after the Amendment Effective Date, BMS shall have no rights to designate new Collaboration Targets under Section 3.3(a) or 3.3(c)(i) of the Agreement;
(g)during the Replacement Period, BMS shall have the right to designate  [*] Reserved Targets for one or more Cardiovascular Disease(s) using the process in Section 3.4 of the Agreement, Section 3.3(b) of the Agreement will not apply to the designation of such Reserved Targets, such Reserved Targets shall be BMS Proprietary Targets, and during the Replacement Period, uniQure shall have no right to, directly or indirectly, have any discussions or engage in any other activities with any Third Party regarding a possible collaboration or license with respect to any Reserved Target or any Variant thereof nor any right to initiate or engage in any other activities with respect to an internal program for any Reserved Target or any Variant thereof; and
(h)from and after the Amendment Effective Date, BMS shall have the right to replace [*] Collaboration Targets with Replacement Targets pursuant to Section 3.3(c)(ii) of the Agreement, as amended below.
For clarity, (A) in the event that BMS designates any Target as a Reserved Target during the Replacement Period, at the end of the Replacement Period, any Reserved Target will cease to be a Reserved Target, and (B) BMS will have no right to designate any Target as a Reserved Target after the Replacement Period.
3.2Amendment of Article 1; Certain Defined Terms.
(a)The definition of “Therapeutic” in Section 1.175 of the Agreement is hereby deleted and replaced with the following:
“Therapeutic” means (a) any Target Therapeutic discovered, owned or Controlled by or for uniQure or any of its Affiliates as part of the performance of the Research Program, (b) any Target Therapeutic for a Collaboration Target discovered by or for uniQure or any of its Affiliates (i.e., whether or not as part of the performance of the Research Program) as of the Effective Date or thereafter during the Term, (c) any peptide or any AAV derived vector with a Collaboration Target that is generically or specifically claimed by a Valid Claim of the uniQure Patents, (d) any Target Therapeutic discovered by BMS or any other Related Party as part of the performance of the Research Program, and (e) any Target Therapeutic for a Collaboration Target which BMS’ manufacture, approved use or sale thereof would infringe a Valid Claim of the uniQure Patents but for the exclusive license granted to BMS under this Agreement.  For clarity, the inclusion of “Collaboration Target” in clause (c) does not limit the AAV derived vectors that are included in the uniQure Technology licensed to BMS under this Agreement.
New Defined Terms.  Article 1 of the Agreement is hereby amended to add the following new definitions:
“CoC Opt-Out Period” has the meaning set forth in the definition of Indication Exclusivity Opt-Out Period.
“Exclusive Indication” means [*].
“Non-Exclusive Indication” means  [*].
​

3

​
“Indication Exclusivity Opt-Out Period” means (a) the period commencing on the Amendment Effective Date and ending on [*] anniversary of the Amendment Effective Date, and (b) if the first Change of Control Transaction of uniQure occurs after  [*] anniversary of the Amendment Effective Date, the [*] period following the effective date of such Change of Control Transaction (such [*] period, the “CoC Opt-Out Period”).
“Replacement Period” has the meaning set forth in Section 3.3(c)(ii).
3.3Replacement Targets.  Section 3.3(c)(ii) of the Agreement is hereby deleted and replaced with the following:
(ii) Replacing a Collaboration Target.  During the period from the Amendment Effective Date until  [*] anniversary thereof (the “Replacement Period”), BMS shall have the right to replace any of the Existing Collaboration Targets, and after the first such replacement, any then-current Collaboration Target, with a new Target for one or more Cardiovascular Disease(s) (a “Replacement Target”) in accordance with and subject to the Excluded Target process as described in Section 3.4; provided however, that (A) BMS may replace a Collaboration Target hereunder no more than  [*], and (B) if BMS is replacing a Collaboration Target with a Reserved Target, BMS may do so by written notice to the JSC without following the Excluded Target process in Section 3.4.  For the avoidance of doubt, no Target Designation Fee is due or payable for a Replacement Target.
3.4Excluded Targets and Non-Exclusive Indications.  Section 3.4 of the Agreement is hereby deleted and replaced with the following:
Excluded Target and Non-Exclusive Indication Process; Designation of Reserved Targets and Replacement Targets for Collaboration Targets.
(a)Target Reviewer.
(i)If, during the Replacement Period, BMS desires to add a Reserved Target (which BMS may do  [*]) or propose a new Target as a Replacement Target for a Collaboration Target, BMS shall notify uniQure through the Joint Discovery Working Group of (A) such Target, (B) the Collaboration Target that is being replaced (if applicable), and (C) the proposed Exclusive Indication(s) for which BMS intends to Develop Therapeutics, which Exclusive Indications may be Cardiovascular Diseases only.  Within  [*] after such notification, uniQure shall provide an independent reviewer mutually agreed to by BMS and uniQure (the “Target Reviewer”) with an updated Excluded Target list (which shall include the Target identification information for each Excluded Target) and Non-Exclusive Indication list.  Within  [*] after uniQure has provided the Target Reviewer with such updated Excluded Target list and Non-Exclusive Indication list, BMS shall provide to the Target Reviewer the Target BMS proposes to become a Replacement Target (and thereby, a Collaboration Target) or Reserved Target and the corresponding proposed Exclusive Indication(s).  Within  [*] thereafter, the Target Reviewer shall notify BMS whether or not the proposed Target is an Excluded Target and, if such proposed Target is not an Excluded Target, whether or not each of the proposed Exclusive Indications is a Non-Exclusive Indication.  If the proposed Target is not an Excluded Target, BMS shall then
​

4

​
have the right to designate such Target as a Collaboration Target or Reserved Target, as the case may be, in accordance with Section 3.4(b).   [*].
(ii)In the case where BMS is considering a Target as a potential Replacement Target or potential Reserved Target and does not want to bring such Target to the attention of uniQure through the Joint Discovery Working Group before determining whether such Target is an Excluded Target, then BMS shall request uniQure to provide an updated Excluded Target list and updated Non-Exclusive Indication list to the Target Reviewer within  [*] after such request without obligation to specify the Target or proposed Exclusive Indication for which the Target Reviewer process shall be initiated. Within  [*] after uniQure has provided the Target Reviewer with such updated lists, BMS shall provide to the Target Reviewer the Target BMS proposes to become a Replacement Target or Reserved Target and the proposed Exclusive Indication(s).  Within  [*] thereafter, the Target Reviewer shall notify BMS whether or not the proposed Target is an Excluded Target and, if such proposed Target is not an Excluded Target, whether or not each of the proposed indications is a Non-Exclusive Indication.  If the proposed Target is not an Excluded Target, BMS shall have the right to designate such Target as a Collaboration Target or Reserved Target, as the case may be, in accordance with Section 3.4(b).  BMS  [*] and shall not be obliged to disclose to uniQure for which Target the Target Reviewer function was performed.
(b)Consultation with uniQure; Designation of Reserved Target or Replacement Target for a Collaboration Target and any Exclusive Indication(s).  Promptly after the Target Reviewer has indicated that the proposed Target is not an Excluded Target, BMS shall notify uniQure through the Joint Discovery Working Group with respect to such proposed Target, including providing the Joint Discovery Working Group the Target identification information with respect to such Target and proposed Exclusive Indications for such Target.  The Joint Discovery Working Group shall discuss the proposed Collaboration Target or Reserved Target, as the case may be, and the proposed Exclusive Indications for such Target; provided however, that BMS shall have the final decision making authority with respect to the designation of a proposed Target as a Collaboration Target or Reserved Target, as the case may be, provided that such Target is not an Excluded Target.  BMS may designate such Target as a Collaboration Target or Reserved Target, as the case may be, by written notification to uniQure, and in conjunction with the designation of such proposed Target as a Collaboration Target by BMS, uniQure shall deliver a certificate for such proposed Target substantially in the form attached to this Agreement as Exhibit G.  Where a proposed indication is a Non-Exclusive Indication at the time such Target is designated as a Collaboration Target, or if there is no scientific rationale or therapeutic applicability for such proposed Exclusive Indication, then such indication will not be an Exclusive Indication.  Where a proposed indication is a Non-Exclusive Indication at the time such Target is designated as a Reserved Target, or if there is no scientific rationale or therapeutic applicability for such indication, when and if such Reserved Target is subsequently designated by BMS as a Replacement Target, such indication will not be an Exclusive Indication.
(c)Adding a New Exclusive Indication.  If, during the Replacement Period, BMS desires to propose a new potential Exclusive Indication for
​

5

​
any Collaboration Target, BMS shall notify uniQure of such potential Exclusive Indication for which BMS intends to Develop Therapeutics through the Joint Discovery Working Group.  Within  [*] after such notification, uniQure shall provide a Target Reviewer with an updated Non-Exclusive Indication list.  Within  [*] after uniQure has provided the Target Reviewer with such updated Non-Exclusive Indication list, BMS shall provide to the Target Reviewer the proposed Non-Exclusive Indication.  Within  [*] thereafter, the Target Reviewer shall notify BMS whether or not the proposed Exclusive Indication is a Non-Exclusive Indication.  If the proposed Exclusive Indication is not a Non-Exclusive Indication and there is a scientific rationale and therapeutic applicability for such indication, it will become an Exclusive Indication, and BMS will promptly thereafter provide an updated Development Plan including Development activities for such Exclusive Indication to the JSC.  BMS shall pay all fees and expenses of the Target Reviewer for performing this Target Reviewer function.  For clarity, BMS shall not have the right to add an Exclusive Indication after the Replacement Period.
(d)Alternative Procedure.  For purposes of the designation of any particular Target as a Replacement Target or Reserved Target or the designation of any indication as an Exclusive Indication, the Parties may mutually agree to not utilize the Target Reviewer, and instead allow the Joint Discovery Working Group to consider any particular Target as a Replacement Target or Reserved Target and any indication as an Exclusive Indication, and allow BMS to designate such particular Target as a Replacement Target or Reserved Target or such indication as an Exclusive Indication without utilizing the Target Reviewer.
3.5Manufacturing.  Section 6.2 of the Agreement is hereby deleted and replaced with the following:
Manufacturing Overview.
(a) Within the scope of the licenses granted in Section 7.1(a) and (b) and subject to the payment obligations of BMS pursuant to Article 8 and the provisions set forth in Section 6.3, BMS shall, notwithstanding anything to the contrary herein, have (i) the exclusive right and will be solely responsible for the manufacture of Therapeutics that are not for Gene Therapy (e.g., peptides) and Products containing such Therapeutics (“Non-Gene Therapy Therapeutics” and “Non-Gene Therapy Products”, respectively) itself or through one or more Affiliates or Third Parties selected by BMS, and (ii) the right, but not the obligation, to manufacture Therapeutics that are for Gene Therapy and any Products containing any such Therapeutics itself or through one or more Affiliates or Third Parties selected by BMS.  Where BMS exercises its right to so manufacture any amount of any Therapeutic that is for Gene Therapy and any Product containing any such Therapeutic, uniQure shall have no obligations in connection with the manufacture of such amount of such Therapeutic and such Product manufactured by BMS or its Affiliate or any Third Party.
(b) For all Therapeutics and Products that are for Gene Therapy, uniQure shall be responsible for the manufacture and supply of such Therapeutics and Products.  Supply of Therapeutics for research and pre-clinical purposes will be conducted under Schedule 3.5 to the Amendment.  Clinical supply will be conducted pursuant to that certain Master Clinical Supply Agreement, dated April 25, 2017, as amended on the Amendment Effective Date, between uniQure and E.R. Squibb and Sons, LLC, an Affiliate of BMS (the “Clinical Supply Agreement”).  The Parties (or their respective Affiliates) shall enter into a commercial supply agreement that shall contain the provisions set forth in Exhibit J except for those pertaining to clinical supply and the termination provisions, which shall be modified to permit BMS (or the Applicable Affiliate(s)) to terminate such commercial supply agreement in its entirety or on a Collaboration Target-by-Collaboration Target, Therapeutic-by-Therapeutic or Product-by-Product basis and to terminate any statement of work under such commercial supply agreement at any time without 

6

cause on  [*] prior written notice, in each case subject to payments, if any, to uniQure set forth in such agreement (the “Commercial Supply Agreement”), and shall enter into the Commercial Supply Agreement no later than  [*].  Schedule 3.5 of the Amendment, the Clinical Supply Agreement and the Commercial Supply Agreement are hereinafter, individually and collectively, the “Supply Agreement(s)”.  Notwithstanding anything to the contrary in this Agreement or any Supply Agreement, BMS (or the applicable Affiliate(s)) may terminate any Supply Agreement in its entirety or on a Collaboration Target-by-Collaboration Target, Therapeutic-by-Therapeutic or Product-by-Product basis and may terminate any statement of work under any Supply Agreement at any time without cause on  [*] prior written notice, in each case subject to payments, if any, to uniQure set forth in the applicable Supply Agreement. For clarity, nothing contained herein will limit any of BMS’ rights hereunder, including BMS’ right to manufacture Therapeutics that are for Gene Therapy and any Products containing any such Therapeutics itself or through one or more Affiliates or Third Parties selected by BMS as set out in Section 6.2(a).
(c) Notwithstanding anything to the contrary herein or in any of the Supply Agreement(s), (i) uniQure shall conduct its manufacture and supply obligations hereunder and under the Supply Agreement(s) using  [*], and (ii) if BMS desires that any Therapeutic be manufactured and supplied using  [*], the “Other Platforms”), BMS shall have the right to manufacture and supply, or have manufactured and supplied, any or all of its requirements of any such Therapeutic using any Other Platform and shall be solely responsible for such manufacture and supply, at its sole expense, and uniQure shall have no rights or obligations in connection with such manufacture and supply (and, for clarity, (A) neither BMS nor any of its Affiliates will have any obligations to uniQure hereunder or otherwise with respect to such manufacture and supply of any Therapeutic using any such Other Platform, and (B) for as long as a Collaboration Target remains a Collaboration Target, any Therapeutics and Products manufactured for such Collaboration Target using any Other Platform will be subject to all other terms of the Agreement, including all payment obligations of BMS, except that there will be no payment obligation for the Manufacturing Cost-Based Component of Supply Price).
3.6Third Party Manufacturing.  Section 6.3 of the Agreement is hereby deleted and replaced with the following:
Third Party Manufacturing. Within the scope of the licenses granted in Section 7.1(a) and (b) and subject to the payment obligations of BMS pursuant to Article 8 and the provisions set forth in Section 6.2, BMS may exercise any of its manufacturing rights (including any have made rights) with respect to any (i) Non-Gene Therapy Therapeutics and Non-Gene Therapy Products, and (ii) Therapeutics and Products for Gene Therapy, in each case, through one or more Third Party manufacturers; provided however, that the Third Party manufacturer undertakes in writing obligations of confidentiality and non-use regarding Confidential Information of uniQure (including uniQure Manufacturing Technology received by such Third Party manufacturer) that are consistent with those undertaken by the Parties pursuant to Article 12 hereof; provided further, that  [*].  Such Third Party manufacturers shall be obligated in writing not to use the uniQure Know-How and uniQure Manufacturing Technology for any use, other than [*].
3.7Restatement of Exclusive License and Limitations.  Sections 7.1(a) and 7.1(e) of the Agreement are hereby restated as the following Section 7.1(a):
(a)Exclusive License Grant.  Subject to the terms and conditions of this Agreement and the terms and conditions of any Third Party agreement that are applicable to a sublicensee under such Third Party agreement (including the Existing License Agreements), uniQure hereby grants to BMS an exclusive (even as to uniQure, except as provided in Section 7.3) license, with the right to grant sublicenses (through 

7

multiple tiers) as provided in Section 7.2, under the uniQure Technology to research, develop, make, have made, use, sell, offer for sale, export and import (including the exclusive right to Develop and Commercialize) Collaboration Targets, Therapeutics and Products in the Field in the Territory.  Without limiting the generality of the foregoing terms of this Section 7.1(a), the license granted by uniQure to BMS pursuant to this Section 7.1(a) shall include, subject to the terms and conditions of this Agreement and the terms and conditions of any Third Party agreement that are applicable to a sublicensee under such Third Party agreement (including the Existing License Agreements), an exclusive (even as to uniQure, except as provided in Section 7.3) sublicense, with the right to grant sublicenses (through multiple tiers) as provided in Section 7.2, under the Information and Patents included in the uniQure Technology and licensed to uniQure under any Third Party Agreements to which uniQure is a party, to research, develop, make, have made, use, sell, offer for sale, export and import (including the exclusive right to Develop and Commercialize) Collaboration Targets, Therapeutics and Products in the Field in the Territory.  For clarity, BMS’ licenses under this Section 7.1(a) and Sections 7.1(b) and (c) shall cover only Collaboration Targets, and Therapeutics and Products with respect to the applicable Collaboration Target, and only for so long as the applicable Collaboration Target remains a Collaboration Target (i.e., has not been replaced or terminated).  Accordingly, the licenses under this Section 7.1 with respect to a particular Collaboration Target, and Therapeutics and Products with respect to such Collaboration Target, shall terminate when such Collaboration Target is terminated or replaced and is therefore no longer a Collaboration Target.  For further clarity, subject to the terms of this Agreement and any Supply Agreement, BMS and its Affiliates shall have the right to use Third Parties to assist with, and/or to conduct, discovery, research, development, pre-clinical, clinical, commercial and other activities with respect to the Therapeutics for the Collaboration Targets, including studies, testing and validation, and the right for BMS to make and have made Therapeutics and research grade and other materials (including uniQure Materials) (itself or by any of its Affiliates or any Third Parties selected by BMS) to conduct research, pre-clinical, development, commercial and other activities.
3.8Indication Exclusivity.  Section 11.1(d) of the Agreement (which for clarity includes only the first clause thereof and not the subsequent paragraphs) is hereby deleted and replaced with the following:
“for as long as BMS is pursuing the Development of or is Commercializing a Therapeutic or Product for any Exclusive Indication, with respect to discovery, research, Development or Commercialization activities for such Exclusive Indication in the Field in the Territory (including with respect to discovery or research activities for the purpose of identifying Target Therapeutics for such Exclusive Indication).”
3.9Indication Exclusivity Opt-Out.  A new Section 11.2 is hereby added to the Agreement as follows:
Indication Exclusivity Opt-Out.  At any time during the Indication Exclusivity Opt-Out Period, uniQure (or as the case may be, its successor in interest) may opt out of the exclusivity obligations under Section 11.1(d) with respect to a particular indication by written notice to BMS (such notice, the “Opt-Out Notice” and such indication, the “Opt-Out Indication”).  uniQure may exercise such right to opt out up to  [*].  Upon BMS’ receipt of the Opt-Out Notice (the “Opt-Out Exercise”), the following will apply:
(a)All payments under Sections 8.3, 8.4 and 8.5 will be reduced by  [*] of the amounts otherwise payable under such sections and, in addition, if the Opt-Out Exercise occurs during the CoC Opt-Out Period, uniQure shall refund to BMS  [*] of all amounts previously paid by BMS under Sections 8.3, 8.4 and 8.5.  Such reduction will apply for each Opt-Out Exercise.  For example, [*]. For the avoidance of doubt, and notwithstanding anything contained herein to the contrary, for each Opt-Out Exercise, payments under Sections 8.3, 8.4 and 8.5 will be reduced for all of the Collaboration Targets, not just the Collaboration Target(s) for which the Opt-Out Indication is being worked on by BMS.

8

(b)BMS shall not be obligated to inform the JSC or any subcommittees or working groups of its Development activities with respect to Therapeutics and Products for the Collaboration Target to which the Opt-Out Indication relates, to the extent such activities are for the Opt-Out Indication, except to the extent necessary for uniQure to conduct its obligations under this Agreement or any separate agreement for the supply of Therapeutics and Products for Gene Therapy for research purposes or any Supply Agreement.
(c)uniQure shall establish and maintain appropriate firewalls to segregate its independent activities on the Opt-Out Indication and its personnel (and, if applicable, those of its Third Party collaborator) conducting such activities from activities performed by or on behalf of BMS or its Affiliates under this Agreement or any Supply Agreement, in each case for the Collaboration Target(s) to which such Opt-Out Indication relates and the personnel performing such activities, (A) to ensure that no BMS Confidential Information and no Information generated under this Agreement or any Supply Agreement is disclosed to any of such personnel performing such independent activities or used in connection with such independent activities, other than  [*], and (B) to ensure that any and all intellectual property (including know-how, patents, copyright, trademarks and trade secrets), regulatory materials, regulatory filings and approvals, materials and other proprietary Information generated in connection with such independent activities on the Opt-Out Indication [*] will be segregated from activities performed pursuant to this Agreement or any Supply Agreement.  Without limiting the foregoing, such firewalls will include all personnel conducting manufacturing activities, including manufacturing development (e.g., analytical development and process development) [*].
For clarity, the Opt-Out Exercise applies only to exclusivity with respect to the Opt-Out Indication under Section 11.1(d), and will not affect exclusivity under Section 11.1(c) with respect to any Collaboration Target.  For further clarity, when uniQure exercises an Opt-Out Exercise, uniQure shall have no right to work on any Collaboration Target or Variant thereof, including on any Therapeutic for any Collaboration Target for any indication, except as permitted under the paragraphs of Section 11.1 that follow Section 11.1(d).
	4.
	MISCELLANEOUS

4.1Full Force and Effect.  This Amendment amends the terms of the Agreement and is deemed incorporated into the Agreement.  The provisions of the Agreement, as amended by this Amendment, remain in full force and effect.
4.2Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an original and all of which together will constitute one instrument and may be executed and delivered through the use of facsimiles or email of pdf copies of this executed Amendment, and each such scanned or pdf copy of this Amendment that includes a Party’s signature will be deemed an original.
​
​

9

​
IN WITNESS WHEREOF, BMS, uniQure and uniQure N.V. have executed this Amendment, effective as of the Amendment Effective Date.
​
​
	BRISTOL-MYERS SQUIBB COMPANY
	    
	UNIQURE BIOPHARMA B.V.

	​
	​
	​

	By:
	/s/ [*]
	​
	By: 
	/s/ Christian Klemt

	​
	​
	​
	​
	​

	Name:
	[*]
	​
	Name:
	 Christian Klemt

	​
	​
	​
	​
	​

	Title:
	[*]
	​
	Title:
	Chief Accounting Officer & Director

	​
	​
	​

	​
	​
	​

	Solely for purposes of Section 2:
	​
	​

	​
	​
	​

	UNIQURE N.V.
	​
	​

	​
	​
	​

	​
	​
	​

	By:
	/s/ Matthew Kapusta
	​
	​

	​
	​
	​
	​

	Name:
	Matthew Kapusta
	​
	​

	​
	​
	​
	​

	Title:
	Chief Executive Officer & Executive Director
	​
	​

​
​

​

​
Schedule 2.2
Net Proceeds; Calculation of Change of Control Payment
​
[*]
​
​

​

​
Schedule 3.1
Existing Collaboration Targets and Exclusive Indications
​
The four Existing Collaboration Targets and Exclusive Indications are:
​
​
 [*]
​
​
​

2

​
​
Schedule 3.5
Research Supply Terms
​
This Schedule 3.5 includes terms and conditions for the supply of research materials by uniQure to BMS.
 [*]

​Exhibit 10.58
​
EXECUTION VERSION
​
*Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
​
This AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”), is dated as of January 29, 2021 and is entered into by and among (a) (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure Bio”), (ii) UNIQURE, INC., a Delaware corporation (“US Borrower” and together with uniQure Bio hereinafter collectively referred to as “Borrower”), (iii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), and (iv) UNIQURE N.V. (formerly uniQure B.V.), a public limited company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 54385229 (“uniQure Holdings” and together with Borrower and uniQure IP, the “Obligors”), (b) HERCULES CAPITAL, INC., a Maryland corporation in its capacity as administrative agent for itself and the Lender (as defined herein) (in such capacity, the “Agent”), and (c) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as “Lender”).  Capitalized terms used herein without definition shall have the same meanings given them in the Amended Loan Agreement (as defined below).
Recitals
​
A.WHEREAS, Obligors, Agent and Lender have entered into that certain Second Amended and Restated Loan and Security Agreement, dated as of May 6, 2016, as amended by Amendment No. 1 to Second Amended and Restated Loan and Security Agreement dated as of December 6, 2018 (as so amended and as may further be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lender has agreed to extend and make available to Borrower certain advances of money;
B.WHEREAS, under the Loan Agreement, there are 2018 Term Loan Advances outstanding in the aggregate principal amount of Thirty-Five Million Dollars ($35,000,000) and Lender has not made any 2018 Term B Loan Advance to Borrower;
C.WHEREAS, Borrower has requested Lender to make available to Borrower term loans in an aggregate principal amount of up to One Hundred Million Dollars ($100,000,000); and
D.WHEREAS, Obligors and Lender have agreed to amend the Loan Agreement upon the terms and conditions more fully set forth herein.
Agreement
​
NOW THEREFORE, in consideration of the foregoing Recitals and intending to be legally bound, the parties hereto agree as follows:
​

1

1.AMENDMENTS.
1.1.Subject to and upon the satisfaction of the conditions specified in Section 4 hereof, the Loan Agreement and certain schedules thereto are hereby amended to reflect the changes which are attached as Exhibit A hereto [*].
1.2.Each reference in the Loan Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan Agreement as amended by this Amendment (the “Amended Loan Agreement”).
2.Borrower’s Representations And Warranties.  Borrower represents and warrants that:
2.1.Immediately upon giving effect to this Amendment (i) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date (in all cases without duplication of any standard(s) of materiality contained in the Loan Documents as to such representations and warranties) and (ii) no Event of Default has occurred and is continuing with respect to which Borrower has not been notified in writing by Agent or Lender.
2.2.Borrower has the corporate or other applicable company power and authority to execute and deliver this Amendment and to perform its obligations under the Amended Loan Agreement.
2.3.[Reserved.]
2.4.The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Amended Loan Agreement have been duly authorized by all necessary corporate or other applicable company action on the part of Borrower.
2.5.Subject to any matters which are set out as qualifications or reservations as to matters of law of general application in the legal opinions delivered to the Lender pursuant to Section 4, this Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and
2.6.As of the date hereof, it has no defenses against the obligations to pay any amounts under the Secured Obligations.  Borrower acknowledges that each of Agent and Lender has acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this Amendment and in connection with the Loan Documents.
Borrower understands and acknowledges that each of Agent and Lender is entering into this Amendment in reliance upon, and in partial consideration for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate.
3.Limitation.  The amendments set forth in this Amendment shall be limited precisely as written and shall not be deemed (a) to be a waiver or modification of any other term or condition of the
​

2

Loan Agreement or of any other instrument or agreement referred to therein or to prejudice any right or remedy which Agent and/or Lender may now have or may have in the future under or in connection with the Amended Loan Agreement or any instrument or agreement referred to therein; or (b) to be a consent to any future amendment or modification or waiver to any instrument or agreement the execution and delivery of which is consented to hereby, or to any waiver of any of the provisions thereof.  Except as expressly amended hereby, the Loan Agreement shall continue in full force and effect.
4.Effectiveness.  This Amendment shall become effective upon the satisfaction of all the following conditions precedent (the date of satisfaction of all such conditions precedent, the “Second Amendment Effective Date”):
4.1.Amendment.  Obligors, Agent and Lender shall have duly executed and delivered this Amendment to Lender.
4.2.Certificates of Authority and Incumbency.  Each Obligor shall have delivered to Agent a certificate, dated the Second Amendment Effective Date and executed by the secretary or equivalent officer of such Obligor, with appropriate insertions and attachments, including:
4.2.1.a copy of its respective certificate or deed of incorporation and current articles of association and bylaws, and for uniQure Bio an extract of its registration in the Trade Register of the Dutch Chamber of Commerce;
4.2.2.a copy of resolutions of its Board and general meeting of shareholders (to the extent required) evidencing approval of (a) this Amendment and the transactions contemplated thereby including the 2021 Term Loan Advances and (b) other transactions evidenced by the Loan Documents;
4.2.3.the names, titles, incumbency and signature specimens of those respective representatives of such Obligor who have been authorized by such resolutions and/or written consents to execute Loan Documents on behalf of such Person; and
4.2.4.for uniQure US, a certificate of good standing from its state of incorporation and similar certificates from all other jurisdictions in which such Borrower does business and where the failure to be qualified would have a Material Adverse Effect.
4.3.Searches. Agent shall have received the results of searches in Delaware, the District of Columbia and Massachusetts with respect to the applicable Obligors, and such searches shall reveal no liens on any of the assets of such Person except for Permitted Liens or Liens to be discharged on or prior to the Second Amendment Effective Date (which liens shall be discharged pursuant to documentation reasonably satisfactory to Agent).
4.4.Perfection Certification.  Each Obligor shall have delivered to Agent an updated perfection certificate.
4.5.Opinion Letters. Agent shall have received a legal opinion of Lender’s Dutch counsel.
​

3

4.6.Advance Request. An Advance Request in respect of the 2021 Term Loan Advance to be requested under Section 2.1.2(a)(i) of the Amended Loan Agreement as described in Section 4.2 of the Amended Loan Agreement.
4.7.Facility Charge.  Borrower shall have paid to Agent a facility fee of three hundred fifty thousand dollars ($350,000).
4.8.Payment of Lender Expenses.  Borrower shall have paid all reasonable and invoiced Lender expenses (including all reasonable and invoiced attorneys’ fees and reasonable expenses) incurred through the date of this Amendment.
5.Release.  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby to the extent possible under applicable law fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.
6.Counterparts.  This Amendment may be signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument.  All counterparts shall be deemed an original of this Amendment.  This Amendment may be executed by facsimile, portable document format (.pdf) or similar technology signature, and such signature shall constitute an original for all purposes.
7.Incorporation By Reference.  The provisions of Section 10 (Miscellaneous) of the Loan Agreement shall be deemed incorporated herein by reference, mutatis mutandis.
8.Loan Documents.  This Amendment shall constitute a Loan Document.
[Remainder of this page intentionally left blank]
​
​

4

​

IN WITNESS WHEREOF, the parties have duly authorized and caused this Amendment to be executed as of the date first written above.
​
	​
	BORROWER:
	​

	​
	UNIQURE BIOPHARMA B.V.

	​
	Signature:
	/s/ Christian Klemt

	​
	Print Name:
	Christian Klemt

	​
	Title:
	Chief Accounting Officer Director

	​
	UNIQURE, INC.

	​
	Signature:
	/s/ Matt Kapusta

	​
	Print Name:
	Matt Kapusta

	​
	Title:
	Chief Executive Officer

	​
	OBLIGOR:
	​

	​
	UNIQURE N.V. (formerly uniQure B.V.)

	​
	Signature:
	/s/ Matt Kapusta

	​
	Print Name:
	Matt Kapusta

	​
	Title:
	Chief Executive Officer

	​
	UNIQURE IP B.V.

	​
	Signature:
	/s/ Christian Klemt

	​
	Print Name:
	Christian Klemt

	​
	Title:
	Chief Accounting Officer Director

​
​

Signature Page to Amendment No. 2 to Loan and Security Agreement

​

Accepted in Palo Alto, California:
​
	​
	AGENT:

	​
	HERCULES CAPITAL, INC.

	​
	​
	​

	​
	By:
	/s/ [*]

	​
	Name:
	[*]

	​
	Its:
	[*]

	​
	​
	​

	​
	​
	​

	​
	LENDER:

	​
	HERCULES CAPITAL FUNDING TRUST 2018-1

	​
	​
	​

	​
	By:
	/s/ [*]

	​
	Name:
	[*]

	​
	Its:
	[*]

	​
	​
	​

	​
	​
	​

	​
	HERCULES CAPITAL FUNDING TRUST 2019-1

	​
	​
	​

	​
	By:
	/s/ [*]

	​
	Name:
	[*]

	​
	Its:
	[*]

	​
	​
	​

	​
	​
	​

	​
	HERCULES CAPITAL, INC.

	​
	By:
	/s/ [*]

	​
	Name:
	[*]

	​
	Its:
	[*]

​
​
​

Signature Page to Amendment No. 2 to Loan and Security Agreement

EXHIBIT A
UNIQURE
SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
THIS SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of May 6, 2016 and is entered into by and among (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure Bio”), (ii) UNIQURE, Inc., a Delaware corporation (“US Borrower” and together with uniQure Bio hereinafter collectively referred to as “Borrower”), (iii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), (iv) each of the subsidiaries of uniQure identified on the Schedule 1 hereto and the signature pages hereof (“uniQure Subsidiaries”), (v) UNIQURE N.V. (formerly uniQure B.V.), a public limited company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 54385229 (“uniQure Holdings” and together with uniQure IP, the uniQure Subsidiaries, and Borrower, the “Obligors”), (vi) the several banks and other financial  institutions or entities from time to time parties to this Agreement (collectively referred to as “Lender”), and (vii) HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (and in such capacity, the “Agent”), and as amended by (a) Amendment No. 1 to Second Amended and Restated Loan and Security Agreement, dated as of the First Amendment Closing Date (as defined below) (the “Amendment No. 1”), by and among the Obligors, Agent and Lender and (b) Amendment No. 2 to Second Amended and Restated Loan and Security Agreement, dated as of the Second Amendment Closing Date (as defined below) (the “Amendment No. 2”), by and among the Obligors, Agent and Lender (as so amended and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Agreement”).
RECITALS
A.WHEREAS, following the execution of this Agreement on May 6, 2016, the parties hereto entered into Amendment No. 1 whereby Lender made available 2018 Term Loan Commitments in respect of a 2018 Term A Loan Advance and a 2018 Term B Loan Advance (in each case as defined below) in an aggregate principal amount of up to Fifty Million Dollars ($50,000,000).
B.WHEREAS, immediately prior to the Second Amendment Closing Date (as defined below), there are 2018 Term Loan Advances outstanding hereunder in the aggregate principal amount of Thirty-Five Million Dollars ($35,000,000) and Lender has not made any 2018 Term B Loan Advance to Borrower.
​

​

C.WHEREAS, Borrower desires to obtain additional term loan commitments in an aggregate principal amount of One Hundred Million Dollars ($100,000,000) for general corporate purposes permitted pursuant to the terms of this Agreement.
D.WHEREAS, the parties hereto desire to further amend this Agreement upon the terms and subject to the conditions set forth herein and in Amendment No. 2 to inter alia provide for such additional term loan commitments and to reduce the 2018 Term Loan Commitment to zero ($0).
NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in this Agreement and the other Loan Documents and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
DEFINITIONS AND RULES OF CONSTRUCTION
Unless otherwise defined herein, the following capitalized terms shall have the following meanings:
“2018 End of Term Charge” shall have the meaning assigned to such term in Section 2.6.
“2018 Prepayment Charge” shall have the meaning assigned to such term in Section 2.4.
“2018 Term A Loan Advance” shall have the meaning assigned to such term in Section 2.1.1(a).
“2018 Term B Loan Advance” shall have the meaning assigned to such term in Section 2.1.1(a).
“2018 Term Commitment” means as to any Lender, the obligation of such Lender, if any, to make a 2018 Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading “2018 Term Loan Advances” under the heading “Commitment” opposite such Lender’s name on Schedule 1.1.
“2018 Term Loan Advance” and “2018 Term Loan Advances” shall have the meaning assigned to such terms in Section 2.1.1(a).
“2018 Term Loan Interest Rate” means for any day, a floating per annum rate equal to the greater of either (a) 8.85%, or (b) the sum of (i) 8.85%, plus (ii) the Prime Rate minus five and one half of one percent (5.50%).
“2018 Term Loan Maturity Date” means June 1, 2023.
“2021 End of Term Charge” shall have the meaning assigned to such term in Section 2.6.
​

8

​

“2021 Term Commitment” means as to any Lender, the obligation of such Lender, if any, to make a 2021 Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading “2021 Term Loan Advances” under the heading “Commitment” opposite such Lender’s name on Schedule 1.1.
“2021 Term Loan Advance” and “2021 Term Loan Advances” shall have the meaning assigned to such terms in Section 2.1.2(a).
“2021 Term Loan Interest Rate” means for any day, a floating per annum rate equal to the greater of either (a) 8.25%, or (b) the sum of (i) 8.25%, plus (ii) the Prime Rate minus three and one quarter of one percent (3.25%).
“2021 Term Loan Maturity Date” means June 1, 2023; provided, however, that if Borrower duly extends the 2021 Term Loan Maturity Date pursuant to Section 2.1.2(e), then the 2021 Term Loan Maturity Date shall mean June 1, 2024 or June 1, 2025, as applicable.
“Account Control Agreement(s)” means any agreement entered into by and among Agent, Borrower and a third party bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Agent a perfected first priority security interest in the subject account or accounts.
“Accounting Standards” means accounting principles used by uniQure Holdings in the preparation of its consolidated financial statements for U.S. Securities Exchange Commission filings, being IFRS or GAAP, as applicable.
“ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.
“Advance” means a Term Loan Advance, a 2018 Term Loan Advance or a 2021 Term Loan Advance.
“Advance Date” means the funding date of an Advance.
“Advance Request” means a request for an Advance submitted by a Borrower to Lender in substantially the form of Exhibit A.
“Affiliate” means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b) any Person directly or indirectly owning, controlling or holding with power to vote twenty percent (20%) or more of the outstanding voting securities of another Person, (c) any Person twenty percent (20%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities, or (d) any Person related by blood or marriage to any Person described in subsection (a), (b) or (c) of this paragraph.  As used in the definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.
“Agreement” has the meaning given to it in the preamble to this Agreement.
​

9

​

“Amendment No. 1” has the meaning given to it in the preamble to this Agreement.
“Amendment No. 2” has the meaning given to it in the preamble to this Agreement.
“Anti-Corruption Laws” shall mean all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.
“Anti-Terrorism Laws” means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.
“Assignee” has the meaning given to it in Section 11.12.
“Blocked Person” means any Person:  (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list.
“Board” means the supervisory board or the single board of directors of uniQure Holdings in place from time to time.
“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower or which Borrower  intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower since its incorporation.
“Business Day” is any day other than a Saturday or Sunday, a day on which Lender is closed or a day on which banks are closed for general business in the Netherlands.
“Cash” means all cash and liquid funds.
“Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of uniQure Holdings or Borrower sale or exchange of outstanding shares (or similar transaction or series of related transactions) of uniQure Holdings’ or Borrower’s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related
​

10

​

transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether uniQure Holdings or Borrower is the surviving entity, or (ii) sale or issuance by uniQure Holdings or Borrower of new shares of Preferred Securities of uniQure Holdings or Borrower to investors, none of whom are current investors in uniQure Holdings or Borrower, and such new Preferred Securities are senior to all existing Preferred Securities and ordinary shares or common stock of uniQure Holdings or Borrower, as applicable, with respect to liquidation preferences, and the aggregate liquidation preference of such new Preferred Securities is more than fifty percent (50%) of the aggregate liquidation preference of all shares of Preferred Securities of uniQure Holdings or Borrower, as applicable.
“Collateral” means the property described in Section 3.
“Collateral Documents” means the security documents described in Section 3.
“Commitment” means as to any Lender, such Lender’s 2018 Term Commitment or 2021 Term Commitment, as the case may be.
“Confidential Information” has the meaning given to it in Section 10.11.
“Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business.  The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.
“continuing” means, with respect to an Event of Default, an Event of Default that has not been remedied or waived.
“Copyright License” means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.
“Copyrights” means all copyrights, whether registered or unregistered, held by the Borrower pursuant to the laws of the Netherlands, or of any other country.
​

11

​

“CSL Licenses” is defined in the definition of “Permitted Liens”.
“Deposit Accounts” means any “deposit accounts,” including any checking account, savings account, or certificate of deposit and any deposit account as defined in the UCC.
“End of Term Charge” means collectively, the charges set forth in Sections 2.5 and 2.6.
“Equity Interests” means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person.
“Event of Default” has the meaning given to it in Section 8.
“Existing 2021 Term Loan Maturity Date” has the meaning given to it in Section 2.1.2(e).
“Existing Loan and Security Agreement” means that certain Amended and Restated Loan and Security Agreement dated as of June 26, 2014 (as the same may have been amended, modified, supplemented or restated and in effect from time to time).
“Extera Judgment” means any settlement or judgment in connection with the currently pending dispute with Extera Partners so long as such settlement or judgment is limited to monetary damages and does not exceed $15,000,000 in the aggregate and no payment is made if an Event of Default has occurred and is continuing.
“Facility Charge” means one and one-quarter of one percent (1.25%) of the original principal amount of the Term Loan advanced on the Original Closing Date.
“Financial Statements” has the meaning given to it in Section 7.1.
“First Amendment Closing Date” means December 6, 2018.
“Funding Documents” means the following: (i) a certificate of good standing for US Borrower from its state of incorporation and from all other US jurisdictions in which it does business to the extent that the failure to be qualified to do business would have a Material Adverse Effect and for uniQure Bio an extract of its registration in the Trade Register of the Dutch Chamber of Commerce, a copy of the deed of incorporation and, if amended after incorporation, the articles of association currently in force and effect; (ii) completed Schedules and Exhibits to this Agreement; (iii) executed originals of the following: (x) the Account Control Agreements, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated and (y) the Perfection Certificate; (iv) legal opinion of Lender’s counsel; (v) the insurance policies and/or endorsements required pursuant to Section 6.1 hereof; (vi) documents, releases, terminations, and other instruments as may be necessary or proper to  release any creditor’s Lien in the Intellectual Property of Borrower including, without limitation, UCC financing statement amendments and appropriate filings with any appropriate register or authority in any jurisdiction; and (vii) and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the
​

12

​

Liens of Lender with respect to all Collateral, in all cases in form and substance reasonably acceptable to Lender.
“GAAP” means generally accepted accounting principles in the United States of America.
“IFRS” are the International Financial Reporting Standards, a collection of guidelines and rules set by the International Accounting Standards Board (www.iasb.org) which are applicable to the circumstances as of the date of determination.
“Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within sixty (60) days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations (as such term is understood under GAAP), and (d) all Contingent Obligations.
“Insolvency Proceeding” is any proceeding by or against any Person under the Dutch Bankruptcy Act, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.
“Intellectual Property” means any and all intellectual property rights in any country or jurisdiction, including but not limited to all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works, utility models, layout-designs (topographies) of integrated circuits, know-how, industrial designs, neighboring rights, database rights or other rights in compilations of data, trade names, internet domain names, plant variety rights and any and all rights of a similar nature, either (i) now known, contemplated or unforeseen, (ii) having a statutory basis or existing under equity, common law or otherwise, or (iii) registered, deposited, filed or not, and including any and all rights in connection with applications for or rights to apply for or acquire any and all of such rights.
“Intra-Group Loans” means the liabilities owed by any Obligor to any other Obligor.
“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person,
“Joinder Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G.
“Leasehold Financing” means any financing entered into by Borrower in respect of improvements of its facilities and/or financed equipment in any location in an aggregate amount of up to $10,000,000.
“Lender” has the meaning given to it in the preamble to this Agreement.
​

13

​

“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests.
“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.
“Loan Documents” means this Agreement, the Notes (if any), the ACH Authorization, the Account Control Agreements, any reaffirmations, the Joinder Agreements, all UCC Financing Statements, the Warrant Agreement, any intellectual property security agreement, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.
“Material Adverse Effect” means a material adverse effect upon: (i) the business, operations, properties, assets or condition (financial or otherwise) of the Obligors, taken as a whole, other than in and of itself (x) the expenditure of cash in the ordinary course, or (y) adverse results of a preclinical or clinical trial or program or the denial, delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration or any other governmental entity with respect to any biologic product or drug; or (ii) the ability of an Obligor to perform the Secured Obligations when due in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens.
“Maximum 2021 Term Loan Amount” means an aggregate principal amount of up to One Hundred Million Dollars ($100,000,000).
“Maximum Rate” shall have the meaning assigned to such term in Section 2.2.
“Note(s)” means a promissory note or promissory notes to evidence an Advance made by a Lender.
“OFAC” is the U.S. Department of Treasury Office of Foreign Assets Control.
“OFAC Lists” are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.
“Ordinary Shares” means the Ordinary Shares, €1 par value per share, of uniQure Bio.
“Original Closing Date” means June 13, 2013.
“Original Term Loan Advances” has the meaning given to it in Section 2.1.1(a).
​

14

​

“Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.
“Patents” means any patent in the Netherlands or in any other country, all registrations and recordings thereof, and all applications for patents of, or rights corresponding thereto, in the Netherlands or any other country.
“Permitted Convertible Debt” means Indebtedness of Borrower consisting of one or more series of notes and notes issued in exchange therefor, that are in each case convertible into Ordinary Shares (or other securities or property following a merger event or other change of the Ordinary Shares), or cash or any combination of cash and Ordinary Shares; provided, however, that such Indebtedness shall (a) be either unsecured or Subordinated Indebtedness, (b) not require any mandatory redemption, prepayment, repurchase, “put”, “call”, or conversion for cash prior to stated maturity other than any customary provision requiring an offer to purchase such notes as a result of a “change of control”, fundamental change, delisting or termination of trading or similar provision, (c) mature after, and not require any scheduled amortization or other scheduled payments of principal prior to, the date that is 181 days after the latest 2021 Term Loan Maturity Date (after giving effect to all possible extensions thereof under Section 2.1.2(e)), and (d) not be guaranteed by any Subsidiary of Borrower.
“Permitted Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Restatement Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $250,000 outstanding at any time secured by a Lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed the lesser of the cost or fair market value of the equipment financed with such Indebtedness; (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $200,000 at any time outstanding, (viii) the Leasehold Financing; (ix) any contingent consideration payable in connection with the acquisition of InoCard in an amount not to exceed €15,000,000 in accordance with the term of the Sale and Purchase Agreement dated as of July 15, 2014 by any among Prof.  Hugo Katus, Prof.  Patrick Most, uniQure Holdings and uniQure Bio (as amended from time to time) (provided however, no cash payments may be made if an Event of Default has occurred and is continuing); (x) any operating leases; (xi) any Intra-Group Loans; (xii) any liability arising pursuant to any guarantee in the form of a declaration of joint and several liability (hoofdelijke aansprakelijkheid) as referred to in article 2:403 Dutch civil code in respect of a member of the group and any residual liability with respect to such declaration arising pursuant to article 2:404 Dutch civil code; (xiii) any joint and several liability arising as a result of (the establishment) of a fiscal unity (fiscale eenheid) between members of the group incorporated in the Netherlands; (xiv) Permitted Convertible Debt not to exceed Five Hundred Million Dollars ($500,000,000) in aggregate principal amount at any time outstanding; (xv) other Indebtedness in an aggregate amount not to exceed $100,000 at any time outstanding, and (xvi) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not
​

15

​

increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.
“Permitted Investment” means: (i) Investments existing on the Restatement Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by any agency or any country thereof maturing within two-years from the date of acquisition thereof, (b) commercial paper maturing no more than two-years from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than two-years from the date of investment therein, and (d) money market accounts; (iii) repurchases of stock from former employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed $500,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of; and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by the Board; (viii) Investments consisting of employee travel advances, employee relocation loans and other employee loans and advances in the ordinary course of business; (ix) Investments in newly-formed Subsidiaries organized in the Netherlands or any other country, provided that such Subsidiaries enter into a Joinder Agreement promptly after their formation by Borrower and execute such other documents as shall be reasonably requested by Lender; (x) joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the nonexclusive licensing of technology, the development of technology or the providing of technical support; (xi) any Intra-Group Loans; and (xii) other Investments that do not exceed $1,000,000 in the aggregate.
“Permitted Liens” means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the Second Amendment Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with Accounting Standards; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other
​

16

​

similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on equipment or software or other intellectual property constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms and any Lien, netting or set-off arrangement granted or entered into by any Obligor under or in connection with the ordinary banking arrangements of such Obligor as a result of the applicable general terms and conditions of the relevant account bank where the Obligor maintains a bank account (including, in respect of an account bank in the Netherlands, the general banking terms and conditions (algemene bankvoorwaarden)); (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness; (xv) Liens incurred in connection with the Leasehold Financing which are limited to the improvements and equipment financed in respect of Borrower’s property located thereon; (xvi) licenses granted by Borrower or its affiliates pursuant to the terms of that certain Commercialization and License Agreement, dated June 24, 2020, by and between uniQure Bio and CSL Berhing LLC, as amended and in effect from time to time (the “CSL Licenses”); and (xvii) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through (xi) and (xv) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.
“Permitted Transfers” means (i) sales of inventory in the normal course of business; (ii) exclusive licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business that could not result in a legal transfer of title of the licensed property; (iii) dispositions of worn-out, obsolete or surplus equipment that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful in the ordinary course of business of Borrower; (iv) other Transfers of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year; (v) the entering into of commercialization, co-development or license agreements with development or collaboration partners in the ordinary course of business; and (vi) the CSL Licenses.
“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.
​

17

​

“Preferred Securities” means at any given time any equity issued by uniQure Holdings or Borrowers, as applicable, that has any rights, preferences or privileges senior to uniQure Holdings’ or Borrower’ ordinary shares or common stock, as applicable.
“Prime Rate” means the “prime rate” as reported in The Wall Street Journal, and if not reported, then the prime rate most recently reported in The Wall Street Journal.
“Restatement Date” shall mean May 6, 2016.
“Sanctioned Country” shall mean, at any time, a country or territory which is the subject or target of any Sanctions.
“Sanctioned Person” shall mean, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.
“Sanctions” shall mean economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom.
“Second Advance End of Term Charge” is defined in Section 2.6.
“Second Amendment Closing Date” means January 29, 2021.
“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation to pay any amount now owing or later arising.
“Subordinated Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion.
“Subsequent Financing” means any equity financing involving the sale and issuance of Borrower’s Equity Interests that is broadly marketed to multiple investors and consummated after the Second Amendment Closing Date, provided, however, that in no event shall the sale and issuance of Borrower’s Equity Interests in any “at-the-market offering” (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended) be deemed a “Subsequent Financing”.
“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which uniQure Holdings owns or controls directly or indirectly 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.
​

18

​

“Term Loan” shall mean the term loans in an aggregate principal amount of up to Fifty Million Dollars ($50,000,000) made available under this Agreement as described in Section 2.1.1.
“Term Loan Advance” means an advance of a Term Loan by a Lender to Borrower pursuant to this Agreement.
“Term Loan Maturity Date” means May 1, 2020.
“Third Advance Facility Charge” means 0.75% of the original principal amount of the aggregate principal amount of the Term Loans advanced pursuant to the Loan Documents.
“Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.
“Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications with any appropriate register or authority in any jurisdiction.
“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.
“Warrant Agreement” means the Warrant Agreement dated as of September 20, 2013 by and between uniQure Holdings and Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.).
Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement.  Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with Accounting Standards, and all financial computations hereunder shall be computed in accordance with Accounting Standards, consistently applied.  Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.
THE LOANS
Reserved.
​

19

​

2018 Term Loan.
(a)First Amendment Closing Date.  Pursuant to the transactions described in this Agreement as amended by Amendment No. 1, on the First Amendment Closing Date, Twenty Million Dollars ($20,000,000) of the principal amount of the Original Term Loan Advances was deemed to constitute and refer to, and was converted into, the 2018 Term A Loan Advance hereunder, without constituting a novation. Such conversion of the Original Term Loan Advances into the 2018 Term A Loan Advance hereunder was deemed an Advance on the First Amendment Closing Date for purposes of this Agreement. In furtherance thereof, the Lenders severally (and not jointly) made, in an amount not exceeding their respective 2018 Term Commitment as in effect on the First Amendment Closing Date, and Borrower agreed to draw, one (1) 2018 Term Loan Advance in an aggregate principal amount of Thirty-Five Million Dollars ($35,000,000) (inclusive of the Original Term Loan Advances) on the First Amendment Closing Date (the “2018 Term A Loan Advance”).  Furthermore, pursuant to the transactions described in this Agreement as amended by Amendment No. 1, on the First Amendment Closing Date, Lender provided severally (and not jointly) its respective 2018 Term Commitment to make one (1) 2018 Term Loan Advance in a principal amount of Fifteen Million Dollars ($15,000,000) (the “2018 Term B Loan Advance”, and together with the 2018 Term A Loan Advance, the “2018 Term Loan Advances”).
Outstanding Principal Amount; Termination of Commitments.  The parties hereto acknowledge and agree that as of the Second Amendment Closing Date: (i) Lender has not made any 2018 Term B Loan Advance to Borrower, (ii) the aggregate outstanding principal amount of the 2018 Term Loan Advances is Thirty-Five Million Dollars ($35,000,000) and (iii) Borrower shall not be permitted to draw, and Lender shall not make, any further 2018 Term Loan Advances.
Interest.  The principal balance of each 2018 Term Loan Advance shall bear interest thereon from such Advance Date at the 2018 Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The 2018 Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time.
Payment.  Borrower will pay interest on each 2018 Term Loan Advance on the first (1st) Business Day of each month, beginning the month after the Advance Date.  The entire 2018 Term Loan Advances principal balance and all accrued but unpaid interest thereon hereunder, shall be due and payable on the 2018 Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each 2018 Term Loan Advance.  Once repaid, the 2018 Term Loan Advances or any portion thereof may not be reborrowed.
1.1.22021 Term Loan.
(a)2021 Term Loan Advances. Subject to the terms and conditions of this Agreement, the Lenders agree severally (and not jointly) to make, in an amount not to exceed
​

20

​

their respective 2021 Term Commitment, at the Borrower’s request in accordance with clause (b) below, (i) one (1) term loan in an aggregate principal amount of Thirty-Five Million Dollars ($35,000,000) on the Second Amendment Closing Date and (ii) after the Second Amendment Closing Date but on or prior to December 15, 2021, additional term loans in an aggregate principal amount not to exceed Sixty-Five Million Dollars ($65,000,000) (each advance of the term loans referred to in Section 2.1.2(a)(i) or (ii), a “2021 Term Loan Advance” and collectively, the “2021 Term Loan Advances”).  The amount of any proposed 2021 Term Loan Advance pursuant to Section 2.1.2(a)(ii) must be a minimum amount of Twenty Million Dollars ($20,000,000).  Only one 2021 Term Loan Advance may be requested in each Advance Request and the aggregate outstanding 2021 Term Loan Advances shall not exceed the Maximum 2021 Term Loan Amount.  Proceeds of each 2021 Term Loan Advance shall be deposited into an account that is subject to a first priority perfected security interest in favor of Agent perfected by an Account Control Agreement.
Advance Request.  To obtain a 2021 Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least (i) in the case of any 2021 Term Loan Advance to be advanced under Section 2.1.2(a)(i), one (1) Business Day before the Advance Date, and (ii) in the case of any 2021 Term Loan Advance to be advanced under Section 2.1.2(a)(ii), at least five (5) Business Days before the Advance Date) to Agent.  Lender shall fund its ratable portion of each 2021 Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such 2021 Term Loan Advance is satisfied as of the requested Advance Date.
Interest.  The principal balance of each 2021 Term Loan Advance shall bear interest thereon from such Advance Date at the 2021 Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The 2021 Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time.
Payment.  Borrower will pay interest on each 2021 Term Loan Advance on the first (1st) Business Day of each month, beginning the month after the Advance Date. The entire 2021 Term Loan Advances principal balance and all accrued but unpaid interest thereon hereunder, shall be due and payable on the 2021 Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each 2021 Term Loan Advance.  Once repaid, the 2021 Term Loan Advances or any portion thereof may not be reborrowed.
Extension of 2021 Term Loan Maturity Date.
(i)Subject to the terms and conditions set forth in clause (ii) below, Borrower may give Agent written notice not later than the date that is thirty (30) days prior to the 2021 Term Loan Maturity Date then in effect hereunder (such 2021 Term Loan Maturity Date then in effect, the “Existing 2021 Term Loan Maturity Date”), that it has elected to extend the 2021 Term Loan Maturity Date by an additional twelve (12) months from the Existing 2021 Term Loan Maturity Date; provided that Borrower may deliver only two (2) such notices of
​

21

​

extension so that the total number of months by which the 2021 Term Loan Maturity Date may be extended under this Section 2.1.2(e) shall not exceed twenty-four (24).
(ii)Notwithstanding the foregoing, no extension of the 2021 Term Loan Maturity Date pursuant to this Section 2.1.2(e) shall be effective unless:
(A) immediately prior to and upon giving effect to such extension (1) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date (in all cases without giving effect to any standard(s) of materiality contained in such Loan Documents as to such representations and warranties), (2) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (3) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; and
(B) Agent shall have received, without limitation, such other documents, agreements, certificates, notices, reports, filings, opinions, financial statements and other writings reasonably requested by Agent in connection therewith.
Maximum Interest.  Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”).  If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of the Secured Obligations consisting of the outstanding principal of the Term Loan Advances, the 2018 Term Loan Advances and the 2021 Term Loan Advances; second, after all principal is repaid, to the payment of Lender's accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.
Default Interest.  In the event any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the past due amount shall be payable on demand.  In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(d), plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(d).
Prepayment.  At its option, Borrower may prepay the whole or part (but in an amount not less than $10,000,000 or less if the applicable amount of outstanding Advances are less than $10,000,000 at such time) of:
​

22

​

Upon at least five (5) Business Days prior written notice to Agent, the outstanding 2018 Term Loan Advances including all accrued and unpaid interest thereon, all unpaid Lender's fees and expenses accrued to the date of the repayment (including, without limitation, the Third Advance End of Term Charge and the 2018 End of Term Charge) together with a prepayment charge equal to the following percentage of the amount of the 2018 Term Loan Advances being prepaid: if such 2018 Term Loan Advance amounts are prepaid in any of the first twelve (12) months following the First Amendment Closing Date, two percent (2%); after twelve (12) months following the First Amendment Closing Date but prior to twenty four (24) months following the First Amendment Closing Date, one and one half percent (1.5%); and after twenty four (24) months following the First Amendment Closing Date but prior to the 2018 Term Loan Maturity Date, one percent (1%) (each, a “2018 Prepayment Charge”).  Borrower agrees that the 2018 Prepayment Charge is a reasonable calculation of Lender's lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the 2018 Term Loan Advances.  For the avoidance of doubt, Lender and Agent agree that the 2018 Term A Loan Advances made hereunder does not constitute prepayment of the Original Term Loan Advances.
Upon at least thirty (30) days prior written notice to Agent and only after the date is six months after the Second Amendment Closing Date, the outstanding 2021 Term Loan Advances including all accrued and unpaid interest thereon, all unpaid Lender's fees and expenses accrued to the date of the repayment (including, without limitation, the 2021 End of Term Charge).
Upon the occurrence of a Change in Control, Borrower shall immediately prepay the aggregate outstanding amount of all principal of all Advances and accrued interest thereon through the prepayment date and all unpaid Lender's fees and expenses accrued to the date of the prepayment (including, without limitation, the Third Advance End of Term Charge, the 2018 End of Term Charge and the 2021 End of Term Charge) together with a 2018 Prepayment Charge.
Original End of Term Charge.  On the earliest to occur of (i) October 1, 2016, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge equal to $345,000.  Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Original Closing Date.
Additional End of Term Charges.
On the earliest to occur of (i) June 30, 2018, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall immediately pay Lender an additional charge equal to $250,000 (the “Second Advance End of Term Charge”).  Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of June 26, 2014.
On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall immediately pay Lender an additional charge equal to $970,000 (the “Third Advance End of Term Charge”).  Notwithstanding the
​

23

​

required payment date of such charge, it shall be deemed earned by Lender as of the Restatement Date.
On the earliest to occur of (i) the 2018 Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall immediately pay Lender One Million Seven Hundred Thirty-Two Thousand Five Hundred Dollars ($1,732,500) (the “2018 End of Term Charge”). Notwithstanding the required payment date of such charge, the 2018 End of Term Charge shall be deemed earned by Lender as of the First Amendment Closing Date.
On the earliest to occur of (i) the 2021 Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations in respect of the 2021 Term Loan Advances in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall immediately pay Lender with respect to the 2021 Term Loan Advances a charge equal to following percentages multiplied by the aggregate original principal amount of all 2021 Term Loan Advances extended by Lender (the “2021 End of Term Charge”): (A) 1.65% if the date such payment is required to be made occurs after six (6) months following the Second Amendment Closing Date but prior to nine (9) months following the Second Amendment Closing Date, (B) 2.25% if the date such payment is required to be made occurs after nine (9) months following the Second Amendment Closing Date but prior to twelve (12) months following the Second Amendment Closing Date, (C) 3.85% if the date such payment is required to be made occurs after twelve (12) months following the Second Amendment Closing Date but prior to twenty-four (24) months following the Second Amendment Closing Date and (4) 4.85% if the date such payment is required to be made occurs after twenty-four (24) months following the Second Amendment Closing Date; provided, however that immediately upon the effectiveness of each separate twelve (12) month extension of the 2021 Term Loan Maturity Date pursuant to Section 2.1.2(e), each of the foregoing percentages shall be increased by one percent (1%).  For the avoidance of doubt, if the 2021 Term Loan Maturity Date is extended twice under Section 2.1.2(e), then each of the foregoing percentages used to calculate the 2021 End of Term Charge shall be increased by two percent (2%) in total.  Notwithstanding the required payment date of such charge, the 2021 End of Term Charge shall be deemed earned by Lender, as to such 2021 Term Loan Advance, as of each date a 2021 Term Loan Advance is made.
Notes.  If so requested by Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender (and/or, if applicable and if so specified in such notice, to any person who is an assignee of Lender pursuant to Section 11.12) (promptly after the Borrower’s receipt of such notice) a Note or Notes to evidence an Advance made by a Lender.
Commitment Fee; Facility Charge.  The parties acknowledge and agree that Borrower paid to Lender (i) a commitment fee of $45,000 on or before the Original Closing Date, and such commitment fee was fully earned on the Original Closing Date and non-refundable regardless of the early termination of this Agreement, (ii) the Facility Charge of $125,000 on the Original Closing Date, and that such Facility Charge was fully earned on the Original Closing Date and non-refundable regardless of the early termination of this Agreement, (iii) the facility charge of $200,000 on June 26, 2014, and such facility charge was fully earned on June 26, 2014 and non-refundable regardless of the early termination of this Agreement, (iv) the Third Advance Facility
​

24

​

Charge of $150,000 on the Restatement Date, and such facility charge was fully earned on the Restatement Date and non-refundable regardless of the early termination of this Agreement, (v) the facility charge of $175,000 on the First Amendment Closing Date, and such facility charge was fully earned on the First Amendment Closing Date and non-refundable regardless of the early termination of this Agreement and (vi) the facility charge of $350,000 on the Second Amendment Closing Date, and such facility charge was fully earned on the Second Amendment Closing Date and non-refundable regardless of the early termination of this Agreement.
Pro Rata Treatment.  Each payment (including prepayment) on account of any fee and any reduction of the 2018 Term Loan Advances shall be made pro rata according to the 2018 Term A Loan Advance of the relevant Lender.  Each payment (including prepayment) on account of any fee and any reduction of the 2021 Term Loan Advances shall be made pro rata according to such 2021 Term Loan Advance of the relevant Lender.
SECURITY INTEREST
As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the Secured Obligations:
uniQure Holdings grants to Lender a first ranking right of pledge on its shares in uniQure Bio and uniQure IP;
uniQure Bio grants to Lender a first ranking right of pledge on its shares in its Dutch subsidiaries identified on the Schedule 1 hereto and a security interest in 100% of the capital stock of US Borrower;
Obligor (excluding US Borrower) grants to Lender a first ranking right of pledge on its (a) trade, intercompany and insurance receivables; (b) movable assets and (c) Deposit Accounts; and
US Borrower grants to Lender a security interest in all of US Borrower’s right, title, and interest in and to the following personal property whether now owned or hereafter acquired: (a) receivables; (b) equipment; (c) fixtures; (d) general intangibles (except as described below); (e) inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of US Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, US Borrower and wherever located, and any of US Borrower’s property in the possession or under the control of Lender; and, to the extent not otherwise included, all proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing, (a), (b), (c) and (d) collectively, the “Collateral”.
Notwithstanding anything in this Agreement or any other Loan Document to the contrary, in no event shall the Collateral include, and the Obligor shall not be deemed to have granted a security interest in: (i) Intellectual Property; provided, however, that the Collateral shall include all accounts and general intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”); or (ii) any of the Borrower’s rights or interests in or under, any license, contract, permit, instrument, security or franchise to which the Borrower is a party or any of its rights or
​

25

​

interests thereunder to the extent, but only to the extent, that such a grant would, under the terms of such license, contract, permit, instrument, security or franchise, result in a breach of the terms of, or constitute a default under, such license, contract, permit, instrument, security or franchise (other than to the extent that any such term would be rendered ineffective pursuant to the UCC or any other applicable law (including the Dutch and the United States Bankruptcy Code) or principles of equity); provided, that immediately upon the ineffectiveness, lapse or termination of any such provision the Collateral shall include, and the Borrower shall be deemed to have granted a security interest in, all the rights and interests described in the foregoing clause (ii) as if such provision had never been in effect.  Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Lender’s security interest in the Rights to Payment.
CONDITIONS PRECEDENT TO ADVANCES
The obligation of Lender to make the 2021 Term Loan Advances hereunder is subject to the satisfaction by Borrower of the following conditions:
Closing Documents.  On or prior to the Advance of the 2021 Term Loan Advances under Section 2.1.2(a)(i) only, Borrower shall have delivered to Lender each of the documents, certificates and other items required pursuant to Section 4 of the Amendment No. 2 and satisfaction of all conditions precedent thereto.
Advance Request.  Borrower shall have delivered to Lender the following: (a) an Advance Request for the relevant Advance as required by 2.1.2(b), duly executed by uniQure Holdings’ Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer and (b) any other documents Lender may reasonably request.
Other conditions to Advances.
The representations and warranties set forth in this Agreement and in Section 5 shall be true and correct in all material respects on and as of the relevant Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.
Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed.
The Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in Section 4.4 and as to the matters set forth in the Advance Request.
No Default.  As of the relevant Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.
​

26

​

REPRESENTATIONS AND WARRANTIES OF BORROWER
Borrower represents and warrants that:
Corporate Status.  uniQure Bio is a private limited liability company duly incorporated and existing under the laws of the Netherlands, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect.  uniQure Bio’s present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by uniQure Bio in a written notice (including any Compliance Certificate) provided to Lender after the Restatement Date.  US Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect.
Collateral.  The relevant Obligor owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens.  Each Obligor has the power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations.
Consents.  Borrower’s execution, delivery and performance of the Notes (if any), this Agreement and all other Loan Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s articles of association, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any contract or agreement or require the consent or approval of any other Person which has not already been obtained.  The individual or individuals executing the Loan Documents are duly authorized to do so.
Material Adverse Effect.  No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.  Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect.
Actions Before Governmental Authorities.  Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of uniQure Holdings, threatened against or affecting Borrower or its property (i) which seek to prevent, enjoin, hinder or delay the transactions contemplated by the Loan Documents or (ii) as to which there is a reasonable possibility of an adverse determination and which, if adversely determined, would reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect on Borrower’s business.
Laws.  Borrower, to its knowledge, is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.  Borrower, to its knowledge, is not in default in any manner under any provision of any
​

27

​

agreement or instrument evidencing indebtedness, or any other material agreement to which it is a party or by which it is bound and for which such default would reasonably be expected to have a Material Adverse Effect on Borrower’s business.
Neither Borrower nor any of its Subsidiaries is an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended, as applicable.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors, as applicable).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act, as applicable.  Neither Borrower nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as each term is defined and used in the Public Utility Holding Company Act of 2005, as applicable.  Neither Borrower’s nor any of its Subsidiaries’ properties or assets has been used by Borrower or such Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.
None of Borrower, any of its Subsidiaries, or any of Borrower’s or its Subsidiaries’ Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.  None of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.
Information Correct and Current.  No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained, contains or will contain any material misstatement of fact or omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not misleading at the time such statement was made or deemed made.  Additionally, any and all financial or business projections provided by Borrower to Lender shall be (i) provided in good faith and based on the most current data and information available to
​

28

​

Borrower, (ii) the most current of such projections provided to the Board, and (iii) are based on reasonable assumptions not viewed as facts and that actual results during the period or periods covered by such projections and forecast may differ from the projected or forecasted results.
Tax Matters.  Except as described on Schedule 5.8, (a) Borrower has filed all federal, state and local tax returns that it is required to file, (b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any tax assessment received by Borrower for the three (3) years preceding the Restatement Date, if any (including any taxes being contested in good faith and by appropriate proceedings).
Intellectual Property Claims.  Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property.  Except as described on Schedule 5.9, (i) each of the material Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no claim has been made in writing to Borrower that any material part of the Intellectual Property violates the rights of any third party.  Exhibit D is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses and other licenses for over-the-counter software), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Restatement Date.  Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to uniQure Holdings’ knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.
Intellectual Property.  Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business, will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower, Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign Intellectual Property without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are necessary in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products.
Borrower Products.  Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material manner Borrower’s use, transfer or licensing thereof or that may materially affect the validity, use or enforceability thereof.  There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or
​

29

​

conduct of the business of Borrower or Borrower Products.  Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim.  To Borrower’s knowledge, neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products infringes the Intellectual Property or other rights of others.
Financial Accounts.  Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Restatement Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.
Employee Loans.  Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.
Capitalization and Subsidiaries.  uniQure Holdings’ capitalization as of the Restatement Date is set forth on Schedule 5.14 annexed hereto.  uniQure Holdings does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.  Attached as Schedule 5.14, as may be updated by uniQure Holdings in a written notice provided after the Restatement Date, is a true, correct and complete list of each Subsidiary.
Centre of main interests and establishments.  uniQure Bio has its “centre of main interests” (as that term is used in article 3(1) of The Council of the European Union Regulation No.  1346/2000 on Insolvency Proceedings) in the Netherlands.
  INSURANCE; INDEMNIFICATION
Coverage.  uniQure Holdings shall cause to be carried and maintained (by itself or its Subsidiaries) commercial general liability insurance, on an occurrence form, against risks customarily insured against in uniQure Holdings’s line of business.  Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3.  uniQure Holdings or its Subsidiaries must maintain a minimum of $1,000,000 of commercial general liability insurance for each occurrence and $2,000,000 in the aggregate.  uniQure Holdings or its Subsidiaries has and agrees to maintain a minimum of $2,000,000 of directors’ and officers’ insurance for each occurrence and $5,000,000 in the aggregate.  So long as there are any Secured Obligations outstanding, uniQure Holdings shall also cause or procure that its Subsidiaries cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard
​

30

​

exceptions and deductibles.  uniQure Holdings or its Subsidiaries shall also carry and maintain a fidelity insurance policy in an amount not less than $100,000.
Certificates.  uniQure Holdings shall deliver to Lender certificates of insurance that evidence uniQure Holdings or its Subsidiaries compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2.  uniQure Holding’s (or its Subsidiaries) insurance certificate shall state Lender is an additional insured for commercial general liability, a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for property insurance and additional insured for liability insurance for any future insurance that uniQure Holdings or its Subsidiaries may acquire from such insurer, unless any right under the liability insurance is restricted from being pledged under Section 7:954(4) of the Dutch Civil Code.  Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance and fidelity.  Unless an Event of Default shall have occurred and be continuing, all insurance proceeds shall be paid or turned over to uniQure Holdings or its Subsidiaries, as applicable.  All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation or any other change adverse to Lender’s interests.  Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver of any of Lender’s rights, all of which are reserved.  Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to Agent updated insurance certificates with respect to such policies.
Indemnity.  Borrower agrees to indemnify and hold Lender and its officers, directors, employees, agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort:, including strict liability in tort), including reasonable documented attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting solely from Lender’s gross negligence or willful misconduct Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement.  This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, the Agreement.
​

31

​

COVENANTS OF BORROWER
Borrower agrees as follows:
Financial Reports.  uniQure Holdings shall furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”):
as soon as practicable (and in any event within 30 days) after the end of each month, its unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against the Obligors) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, all certified by uniQure Holdings’ Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Global Controller to the effect that they have been prepared in accordance with Accounting Standards, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements;
as soon as practicable (and in any event within 60 days) after the end of each calendar quarter, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, certified by uniQure Holdings’ Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Global Controller to the effect that they have been prepared in accordance with Accounting Standards, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments; as well as the most recent capitalization table for the Obligors, including the weighted average exercise price of employee stock options;
as soon as practicable (and in any event within one hundred and eighty (180 days)) after the end of each fiscal year, unqualified audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by uniQure Holdings and reasonably acceptable to Lender, accompanied by any management report from such accountants;
as soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the form of Exhibit F;
promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that US Borrower has made available to holders of its capital stock and copies of any regular, periodic and special reports or registration statements that US Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;
​

32

​

notify Lender in writing at least two (2) weeks in advance of the time and place of any regularly scheduled meeting of the Board (including without limitation telephone, conference call and video meetings).  uniQure Holdings shall give Lender copies of all notices, minutes, consents and other materials uniQure Holdings provides to its directors in connection with said meetings if reasonably requested by Lender;
Borrower at all times shall maintain Cash and/or cash equivalents on deposit in a deposit or security account located in the United States that is subject to an Account Control Agreement of at least the lesser of (i) 65% of the outstanding principal balance of the Advances or (ii) 100% of all of the worldwide Cash and cash equivalents of the Borrower;
as soon as practicable (and in any event within 30 days) of approval by the Board an annual budget for each financial year as well as budgets, operating plans and other financial information with respect to the Obligors reasonably requested by Lender; and
uniQure Holdings shall not make any change in its (a) accounting policies or reporting practices except in accordance with Accounting Standards, or (b) fiscal years or fiscal quarters.  The fiscal year of Borrower shall end on December 31.
The filing of any financial statements, reports or registration statements by uniQure Holdings with the U.S. Securities Exchange Commission (or foreign equivalent thereof) through its electronic filing system shall constitute delivery of such materials to Lender for purposes hereof so long as Borrower timely emails a link of such filings to Lender.
The executed Compliance Certificate may be sent via facsimile to Lender at [*].  All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to [*] provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: [*], attention Chief Credit Officer.
Management Rights.  Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours.  In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records.  In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower.  Such consultations shall not unreasonably interfere with Borrower’s business operations.  The parties intend that the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s management or policies.
Further Assurances.  Borrower shall from time to time execute, deliver and file, alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the highest priority to Lender’s Lien on
​

33

​

the Collateral.  Borrower shall from time to time procure any instruments or documents as may reasonably be requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and protect the Liens granted hereby and thereby.  In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements, security agreements and other documents necessary to grant, perfect and give the highest priority to Lender’s Lien on the Collateral without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower.  Borrower shall protect and defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens.
Indebtedness.  Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion.  Borrower shall not make any payments under the Leasehold Financing if an Event of Default has occurred and is continuing.
Collateral.  Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting the Collateral, the Intellectual Property, such other property and assets, or any Liens thereon.  Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets.  Borrower shall not agree with any Person other than Lender not to encumber its property.
Investments.  Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments.
Distributions.  Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than (i) pursuant to employee, director or consultant repurchase plans, stock option plans or agreements, restricted stock agreements or other similar agreements, provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest or (ii) the delivery of its Ordinary Shares upon conversion of Permitted Convertible Debt; (b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest, except that (i) a Subsidiary may pay dividends or make distributions to Borrower and (ii) Borrower may make cash payments in lieu of issuing fractional shares in connection with a conversion of Permitted Convertible Debt into Ordinary Shares; (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third
​

34

​

party in excess of $250,000 in the aggregate; or (d) waive, release or forgive any indebtedness owed by any employees, officers or directors in excess of $250,000 in the aggregate.
Transfers.  Except for Permitted Transfers, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of their assets.
Mergers or Acquisitions.  uniQure Holdings shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of (i) a Subsidiary into an Obligor, or (ii) of a Subsidiary which is not an Obligor into any Subsidiary or into an Obligor, provided, in each case, that with respect to any merger into an Obligor, Obligor is the surviving entity) or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person.
Taxes.  Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom.  Borrower shall file on or before the due date therefor all personal property tax returns in respect of the Collateral.  Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with Accounting Standards.
Corporate Changes.  Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days’ prior written notice to Lender.  Neither Borrower nor any Subsidiary shall relocate its principal place of business unless it has provided prior written notice to Lender and such relocation is within the Netherlands or the United States or within the same country as its previous location.  Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (x) sales of movable assets in the ordinary course of business, (y) relocations of movable assets having an aggregate value of up to $250,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the Netherlands or the United States or within the same country as its previous location, and (iii) if such relocation is to a third party bailee in the United States, it has used commercially reasonable efforts to deliver a bailee agreement in form and substance reasonably acceptable to Lender.
Deposit Accounts.  No Obligor shall maintain any Deposit Accounts (other than (i) accounts consisting of the proceeds from the Leasehold Financing so long as the aggregate amount in such accounts do not exceed $10,000,000 and (ii) payroll, trust or escrow accounts), or accounts holding Investment Property, except with respect to which Lender has an Account Control Agreement and/or a right of pledge (subject only to a Lien under clause (xii) of the definition of Permitted Liens); provided however, Obligor shall (a) obtain Account Control Agreements for its respective accounts at Rabobank National Association and (b) deliver a completed and executed Perfection Certificate, in each case, no later than 30 Business Days after the Restatement Date.
​

35

​

Subsidiaries.  Borrower shall notify Lender of each Subsidiary formed subsequent to the Restatement Date and, within 15 days of formation, shall cause any such Subsidiary to execute and deliver to Lender a Joinder Agreement.
Pensions.  Borrower shall ensure that all pension schemes operated by or maintained for the benefit of members of the Borrower and/or any of their employees are funded to the extent required by applicable law and regulations where failure to do so would be reasonably likely to have a Material Adverse Effect.
Non-Obligors.  The revenue of Subsidiaries which are not Obligors shall not exceed €250,000 in the aggregate on an annual basis.  The fair market value of the assets of Subsidiaries which are not Obligors shall not exceed €500,000 in the aggregate at any given time.
Use of Proceeds.  Borrower agrees that the proceeds of the Loans shall be used solely to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes.  The proceeds of the Loans will not be used in violation of applicable Anti-Corruption Laws or applicable Sanctions.
Compliance with Laws.
Borrower shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respect with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower’s business.
Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.
Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with applicable Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of Borrower its directors and agents, are in compliance with applicable Anti-Corruption Laws and applicable Sanctions in all material respects.
​

36

​

None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person.  No Loan, use of proceeds or other transaction contemplated by this Agreement will violate applicable Anti-Corruption Laws or applicable Sanctions.
Transactions with Affiliates.  Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than those that might be obtained in an arm’s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary; provided that no such restriction shall apply where the value of any transaction with any Affiliate of Borrower is less than Five Hundred Thousand Dollars ($500,000).
Right to Invest.  Borrower agrees that, prior to the repayment in full of all 2021 Term Loan Advances, Lender, any of its affiliates and/or (subject to Borrower's consent, which consent shall not be unreasonably withheld, conditioned or delayed) any other assignees or nominees, shall have the right, in their discretion, to invest up to an aggregate amount of $2,000,000 in any Subsequent Financing on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing, provided, however, that such aggregate amount for any such Subsequent Financing may be reduced to an amount determined in good faith by the managing underwriter of any such Subsequent Financing if such managing underwriter determines, in its reasonable discretion, that such reduction is required as a result of bona fide marketing factors. Borrower shall notify Lender within twenty-four (24) hours of the public announcement of any such Subsequent Financing and Lender shall notify Borrower of its intention to participate in such Subsequent Financing as soon as possible thereafter, but in any event, not later than eight (8) hours prior to the pricing of such Subsequent Financing.
EVENTS OF DEFAULT
The occurrence of any one or more of the following events shall be an Event of Default:
Payments.  Borrower fails to pay any amount when due under this Agreement or any of the other Loan Documents unless its failure to pay is caused by administrative or technical error and payment is made within three Business Days of its due date; or
Covenants.  Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents (other than a breach or default covered by Section 8.1), and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.1(g), 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.16, 7.17 or 7.19) such default continues for more than 15 Business Days after the earlier of the date on which (i) Agent or Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.1(g), 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.16, 7.17 or 7.19, the occurrence of such default; or
Material Adverse Effect.  A circumstance (other than the Extera Judgment) has occurred that would reasonably be expected to have a Material Adverse Effect; or
​

37

​

Other Loan Documents.  The occurrence of any default under any Loan Document and such default continues for more than 15 Business Days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default; or
Representations.  Any material representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect; or
Insolvency.  Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees; (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) thirty (30) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or
Attachments; Judgments.  Any portion of Borrower’s assets is attached or seized, or a levy is filed against any such assets (and such attachment, seizure or levy is not lifted or released within 30 days), or a judgment or judgments (no longer subject to appeal) (excluding the Extera Judgment) is/are entered for the payment of money, individually or in the aggregate, of at least $2,000,000, unless otherwise waived by Lender in its reasonable discretion, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or
Other Obligations.  The occurrence of any default (beyond any applicable grace, appeal or cure periods) under any agreement or obligation of Borrower involving any Indebtedness in excess of $1,000,000, or the occurrence of any default by the Borrower under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect.
REMEDIES
General.  On and at any time after the occurrence of an Event of Default which is continuing (i) Lender may, at its option, accelerate and demand payment of all or any part of the
​

38

​

Secured Obligations and the 2018 Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 8.6, all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender may notify any of Borrower's account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower's behalf and endorse Lender's name without recourse on any such payment for deposit directly to Lender's account.
Collection; Foreclosure.  Unless otherwise agreed in the Collateral Documents, on and at any time after the occurrence of an Events of Default which is continuing, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender may elect, in each case to the extent permitted under applicable law.  Any such sale may be made either at public or private sale at its place of business or elsewhere.  Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower.  Lender may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower.  The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Lender in the following order of priorities:
First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and expenses as described in Section 11.11;
Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and
Finally, after the full, final, and indefeasible payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.
Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.
No Waiver.  Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral.
Cumulative Remedies.  The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative.  The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Lender.
​

39

​

MISCELLANEOUS
Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.
Notice.  Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:
[*]
​
or to such other address as each party may designate for itself by like notice.
Entire Agreement; Amendments.  This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Lender’s proposal letter dated November 8, 2018).  None of the terms of this Agreement or any of the other Loan Documents may be amended except by an instrument executed by each of the parties hereto.
No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.
No Waiver.  The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers.  No omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter.
Survival.  All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be
​

40

​

for the benefit of Lender and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.
Successors and Assigns.  The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any).  Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Lender’s express prior written consent, and any such attempted assignment shall be void and of no effect.  Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Lender’s successors and assigns.
Governing Law.  This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the Netherlands.
Jurisdiction.  The courts (Rechtbank) of Amsterdam, the Netherlands, subject to ordinary appeal and final appeal shall have exclusive jurisdiction to hear and determine any suit, action or proceeding and to settle any disputes arising out of or in connection with this Agreement and the other Loan Documents (including a dispute regarding the existence, validity or termination of this Agreement or the consequences of its nullity) and, for such purposes, each of the parties hereto irrevocably submits to the exclusive jurisdiction of such courts.  This Section is for the benefit of the Lender only.  As a result, the Lender may take proceedings relating to a dispute in any other courts with jurisdiction.  To the extent allowed by law, the Lender may take concurrent proceedings in any number of jurisdictions.
Professional Fees.  Borrower promises to pay Lender’s documented out-of-pocket fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable documented attorneys’ fees, UCC searches, filing costs, and other miscellaneous expenses up to a maximum amount of $10,000 and Agent confirms as of the Restatement Date that there are no other legal fees owing as of such date.  In addition, Borrower promises to pay any and all reasonable documented attorneys’ and other professionals’ fees and expenses (including fees and expenses of in-house counsel) incurred by Lender after the Restatement Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.
Confidentiality.  Lender acknowledges that all financial statements provided to Lender by Borrower and certain items of Collateral and information provided to Lender by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the “Confidential Information”).  Accordingly, Lender agrees
​

41

​

that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s security interest in the Collateral shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its sole discretion determines that any such party should have access to such information in connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral after the occurrence and during the continuance of an Event of Default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents.
Assignment of Rights.  Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and under the Loan Documents to any person or entity (an “Assignee”).  After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given.  No such assignment by Lender shall relieve Borrower of any of its obligations hereunder.  Lender agrees that in the event of any transfer by it of the Note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.
Revival of Secured Obligations.  This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender.  The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment,
​

42

​

performance, or transfer of Collateral had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash.
Counterparts.  This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.
Publicity.
Borrower consents to the publication and use by Lender and any of its member businesses and affiliates of (i) Borrower’s name (including a brief description of the relationship between Borrower and Lender) and logo for use on Lender’s website and as required for the purposes of filings with or reports to governmental authorities required by law, and (ii) after review and approval by Borrower (a) Borrower’s name and a hyperlink to Borrower’s web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the “Lender Publicity Materials”); (b) the names of officers of Borrower in the Lender Publicity Materials; and (c) Borrower’s name, trademarks or servicemarks in any news release concerning Lender.
Neither Borrower nor any of its member businesses and affiliates shall, without Lender’s consent, publicize or use, for any purpose other than filings with or reports to governmental authorities required by law and the rules of any applicable securities commission or securities exchange, (i) Lender’s name (including a brief description of the relationship between Borrower and Lender), logo or hyperlink to Lender’s web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the “Borrower Publicity Materials”); (ii) the names of officers of Lender in the Borrower Publicity Materials; and (iii) Lender’s name, trademarks, servicemarks in any news release concerning Borrower.
Existing Loan and Security Agreement Amended and Restated.  Upon satisfaction of the conditions precedent to the effectiveness of this Agreement, (a) this Agreement shall amend and restate the Existing Loan and Security Agreement in its entirety (except to the extent that definitions from the Existing Loan and Security Agreement are incorporated herein by reference) and (b) the rights and obligations of the parties under the Existing Loan and Security Agreement shall be subsumed within, and be governed by, this Agreement; provided, however, that the Borrower hereby agrees that all Secured Obligations of the Borrower under, and as defined in, the Existing Loan and Security Agreement and the other Loan Documents shall remain outstanding, shall constitute continuing Secured Obligations secured by the Collateral, and this Agreement shall not be deemed to evidence or result in a novation or repayment and re-borrowing of such obligations and other liabilities.  Borrower hereby acknowledges and reaffirms each and every Loan Document entered into in connection with the Existing Loan and Security Agreement and acknowledges that each such Loan Document remains in full force and effect and enforceable against Borrower in accordance with its respective terms after giving
​

43

​

effect to the execution and delivery of this Agreement without further action by Lender, Borrower or any other Person.  All reference to the “Loan and Security Agreement” in each such Loan Document shall be deemed to be a reference to this Agreement.
Agency.  Lender hereby irrevocably appoints HERCULES CAPITAL, INC. to act on its behalf as agent hereunder and under the other Loan Documents and authorizes the agent to take such actions on its behalf and to exercise such powers as are delegated to the agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.
(SIGNATURES TO FOLLOW)
​
​

44

​

​
	​
	LENDER:

	​
	​

	​
	HERCULES CAPITAL, INC.

	​
	​

	​
	Signature: 
	​

	​
	​
	​

	​
	Print Name: 
	​

	​
	​
	​

	​
	Title:
	​

	​
	​
	​

​

​

​

IN WITNESS WHEREOF, the Obligors and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.
BORROWER:

UNIQURE BIOPHARMA B.V.
by: uniQure N.V., its Managing Director

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  Managing Director
UNIQURE, INC. 

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  President and Secretary
OBLIGORS:

UNIQURE N.V. (formerly uniQure B.V.)

Signature: ​ ​
Print Name: Matt Kapusta
Title: Managing Director
UNIQURE RESEARCH B.V.
by: uniQure Biopharma RV.,
the Company’s Managing Director
by: uniQure N.V., its Managing Director

Signature: ​ ​
Print Name: Matt Kapusta
Title:  Managing Director
​

​

​

UNIQURE ASSAY DEVELOPMENT 
by: uniQure Biopharma B.V.,
the Company’s Managing Director
by: uniQure N.V., its Managing Director

Signature:​ ​
Print Name: Matt Kapusta
Title: Managing Director
UNIQURE QA B.V.
by: uniQure Biopharma B.V.,
the Company’s Managing Director
by: uniQure N.V., its Managing Director
Print Name:  Matt Kapusta
Title:  Managing Director
UNIQURE PROCESS DEVELOPMENT B.V.
by: uniQure .Biopharma B.V.,
the Company’s Managing Director
by: uniQure N.V., its Managing Director
​
​
Signature: ​ ​
Print Name:  Matt Kapusta
Title: Managing Director
UNIQURE, NON CLINICAL B.V.
by: uniQure Biopharma B.V.,
the Company’s Managing Director
by: uniQure N.V., its Managing Director

Signature: ​ ​
Print Name:  Matt Kapusta
Title: Managing Director
UNIQURE CLINICAL B.V.
by: uniQure Biopharma B.V.,
the Company’s Managing Director
Signature: ​ ​
Print Name:  Matt Kapusta
Title: Managing Director
​

​

​

UNIQURE IP B.V.
by uniQure N.V. ,
the Company’s Managing Director
Signature: ​ ​

Print Name:  Matt Kapusta
Title:  Managing Director
​
​

​

​

IN WITNESS WHEREOF, the Obligors and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.
UNIQURE GmbH 

Signature: ​ ​
Print Name: Christian Klemt 
Title: Managing Director
​
​

​

​

Table of Addenda, Exhibits and Schedules
	​

	​

	Exhibit A:
	Advance Request
Attachment to Advance Request

	Exhibit B:
	Note

	Exhibit C:
	Name, Locations, and Other Information for Borrower

	Exhibit D:
	Borrower’s Patents, Trademarks, Copyrights and Licenses

	Exhibit E:
	Borrower’s Deposit Accounts and Investment Accounts

	Exhibit F:
	Compliance Certificate

	Exhibit G:
	Joinder Agreement

	Exhibit H:
	ACH Debit Authorization Agreement

	Schedule 1 
	Subsidiaries

	Schedule 1.1 
	Commitments

	Schedule 1A 
	Existing Permitted Indebtedness

	Schedule 1B 
	Existing Permitted Investments

	Schedule 1C 
	Existing Permitted Liens

	Schedule 5.3 
	Consents, Etc.

	Schedule 5.5 
	Actions Before Governmental Authorities

	Schedule 5.8 
	Tax Matters

	Schedule 5.9
	Intellectual Property Claims

	Schedule 5.10
	Intellectual Property

	Schedule 5.11
	Borrower Products

	Schedule 5.14 
	Capitalization

​
​

​

​

EXHIBIT A
ADVANCE REQUEST
	​

	​

	To: Lender:
	Date                                      , 20    

​
HERCULES CAPITAL, INC.
400 Hamilton Avenue, Suite 310
Palo Alto, CA 94301
Facsimile: [*]
Email: [*]
Attn: Chief Legal Officer and [*]
UNIQURE BIOPHARMA B.V., and UNIQURE, INC., (hereinafter collectively referred to as “Borrower”) hereby requests from HERCULES CAPITAL, INC. (“Lender”) a 2021 Term Loan Advance in the amount of _________________Dollars ($_______________) on                                       (the “Advance Date”) pursuant to the Second Amended and Restated Loan and Security Agreement between, among others, Borrower and Lender (the “Agreement”).  Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement.
SECTION 1. Please:
(a)Issue a check payable to Borrower                                      
or
(h)Wire Funds to Borrower’s account                                      
	Bank:
	​

	Address: 
	​

	ABA Number: 
	​

	Account Number: 
	​

	Account Name:
	​

Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of such Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Agreement are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents.  Borrower understands and acknowledges that Lender has the right to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance.
​

​

​

Borrower hereby represents that Borrower’s corporate status and principal place of business have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request.
Borrower agrees to notify Lender promptly before the funding of the Advance if any of the matters which have been represented above shall not be true and correct on the Advance Date and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date.
Executed as of [                                     ], 2021
BORROWER:

UNIQURE BIOPHARMA B.V.
by: uniQure N.V., its Managing Director

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  Managing Director
UNIQURE, INC. 

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  President and Secretary
ATTACHMENT TO ADVANCE REQUEST
Dated: __________
​
​

​

​

Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows:
	Name:
	​

	Type of organization:
	​

	State of organization:
	​

	Organization file number:
	​

Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its current locations are as follows:
​

​

​

EXHIBIT B
SECOND AMENDED AND RESTATED PROMISSORY NOTE
	​

	​

	SECTION 2. $                                      
	Maturity Date                                      , 20    

FOR VALUE RECEIVED, (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure Bio”), (ii) UNIQURE, Inc., a Delaware corporation (“US Borrower” and together with uniQure Bio hereinafter collectively referred to as “Borrower”) hereby promises to pay to the order of [HERCULES CAPITAL FUNDING TRUST 2014-1, a Delaware statutory trust][ HERCULES CAPITAL, INC., a Maryland corporation] (the “Lender”) or the holder of this Second Amended and Restated Promissory Note (this “Promissory Note”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of this Promissory Note may specify from time to time in writing, in lawful money of the United States of America, the principal amount of _____________________ Dollars ($______________) or such other principal amount as Lender has advanced to
Borrower, together with interest at a floating rate as set forth in Section [2.1.1(d)][2.1.2(d)] of the Loan Agreement referenced below.
This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Second Amended and Restated Loan and Security Agreement dated May 6, 2016, by and between, among others, Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof.  All payments shall be made in accordance with the Loan Agreement.  All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein.  An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note.
​

​

​

Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense.  This Promissory Note has been negotiated and delivered to Lender and is payable in the State of California.  This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the Netherlands, excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction.
BORROWER:

UNIQURE BIOPHARMA B.V.
by: uniQure N.V., its Managing Director

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  Managing Director
UNIQURE, INC. 

Signature: ​ ​
Print Name:  Matt Kapusta
Title:  President and Secretary
​

​

​

EXHIBIT C
NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER
1.uniQure US represents and warrants to Agent that its current name and organizational status as of the First Amendment Closing Date is as follows:
	Name:
	UNIQURE, INC.

	Type of organization:
	Corporation

	State of organization:
	Delaware

	Organization file number:
	5330494

2.uniQure represents and warrants to Agent that its current name and organizational status as of the First Amendment Closing Date is as follows:
	Name:
	UNIQURE BIOPHARMA B.V.

	Type of organization:
	Private Limited Company

	State of organization:
	The Netherlands

	Organization file number:
	34275365

3.Borrower represents and warrants to Agent that for five (5) years prior to the First Amendment Closing Date, Borrower did not do business under any other name or organization or form.
4.Borrower represents and warrants to Agent that its principal executive office is at Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands.
​

​

​

EXHIBIT D
BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES
[PROVIDED SEPARATELY]
​
​

​

​

EXHIBIT E
BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS
[*]
​

​

​

EXHIBIT F
COMPLIANCE CERTIFICATE
SECTION 3. Hercules Capital, Inc. (as “Agent”)
400 Hamilton Avenue, Suite 310
Palo Alto, CA 94301
SECTION 4. Facsimile: [*]
SECTION 5. Email: [*]
SECTION 6. Attn: [*]
​
Reference is made to that certain Second Amended and Restated Loan and Security Agreement dated May 6, 2016 and the Loan Documents (as defined therein) entered into in connection with such Second Amended and Restated Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the “Loan Agreement”) by and among Hercules Capital, Inc. (the “Agent”), the several banks and other financial institutions or entities from time to time party thereto (collectively, the “Lender”) and Hercules Capital, Inc., as agent for the Lender (the “Agent”) and UNIQURE BIOPHARMA B.V. and UNIQURE, Inc., (hereinafter collectively referred to as "Borrower"), as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.
​
The undersigned is an Officer of UNIQURE N.V., knowledgeable of all UNIQURE N.V.'s financial matters, and is authorized to provide certification of information regarding UNIQURE N.V.; hereby certifies that in accordance with the terms and conditions of the Loan Agreement, UNIQURE N.V. is in compliance for the period ending _______________ of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct in all material respects on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies that these are prepared in accordance with Accounting Standards (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the next except as explained below.
​

​

​

SECTION 7. REPORTING REQUIREMENTREQUIREDCHECK IF ATTACHED
SECTION 8. Interim Financial StatementsMonthly within 30 days
SECTION 9. Interim Financial StatementsQuarterly within 60 days
SECTION 10. Audited Financial StatementsFYE within 180 days
SECTION 11. Total Cash Balance      $                                     
SECTION 12. US Accounts Balance  $                                     
Very Truly Yours,

UNIQURE N.V. 

Signature: ​ ​

Print Name: ​ ​

Title:
​
​

​

​

​
EXHIBIT G
FORM OF JOINDER AGREEMENT
This Joinder Agreement (the “Joinder Agreement”) is made and dated as of [                   ], 20[        ], and is entered into by and between                                      , a                                       corporation (“Subsidiary”), and HERCULES CAPITAL FUNDING TRUST 2014-1, a Delaware statutory trust, as agent on behalf itself and other lenders (collectively, “Lender”).
RECITALS
A.Subsidiary’s Affiliates, (i) UNIQURE BIOPHARMA B.V., and UNIQURE, INC., (hereinafter collectively referred to as “Borrower”) have, among others, entered into that certain Second Amended and Restated Loan and Security Agreement dated May 6, 2016, with the lenders party thereto, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith;
B.Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Borrower’s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;
AGREEMENT
NOW THEREFORE, Subsidiary and Lender agree as follows:
1.The recitals set forth above are incorporated into and made part of this Joinder Agreement.  Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.
2.By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith.  Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties, responsibilities or obligations shall flow only to Borrower and not to Subsidiary or any other person or entity.  By way of example (and not an exclusive list): (a) Lender’s providing notice to Borrower in accordance with the Loan Agreement or as otherwise agreed between Borrower and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Borrower shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an Advance or make any other demand on Lender.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
​
​

​

​

[SIGNATURE PAGE TO JOINDER AGREEMENT]
SECTION 13. SUBSIDIARY:

By: ​ ​
Name: ​ ​
Title: ​ ​
Address: ​ ​
Telephone: ​ ​
Facsimile: ​ ​
​
SECTION 14. HERCULES CAPITAL, INC., as agent for Lender

By: ​ ​
Name: ​ ​
Title: ​ ​

Address: 
400 Hamilton Ave., Suite 310 
Palo Alto, CA 94301 
Facsimile:  [*] 
Telephone: [*]
SECTION 15. [*]
​
​

​

​

EXHIBIT H
ACH DEBIT AUTHORIZATION AGREEMENT
SECTION 16. Hercules Capital, Inc. (as “Agent”)
400 Hamilton Avenue, Suite 310
Palo Alto, CA 94301
SECTION 17. Facsimile: [*]
SECTION 18. Email: [*]
SECTION 19. Attn: [*]
SECTION 20. Re:Second Amended and Restated Loan and Security Agreement dated May 2016 between, among others, (i) UNIQURE BIOPHARMA B.V., and UNIQURE, INC., (hereinafter collectively referred to as “Borrower”), the lenders party thereto and HERCULES CAPITAL FUNDING TRUST 2014-1 as agent for itself and the lenders (collectively, “Lender”) (the “Agreement”)
SECTION 21. In connection with the above referenced Agreement, Borrower hereby authorizes the Lender to initiate debit entries for the periodic payments due under the Agreement to Borrower’s account indicated below.  Borrower authorizes the depository institution named below to debit to such account.
	DEPOSITORY NAME
                                                                          
	BRANCH
                                                                          

	CITY
                                                                          
	STATE AND ZIP CODE
                                                                          

	TRANSIT/ABA NUMBER
                                                                          
	ACCOUNT NUMBER
                                                                          

SECTION 22. This authority will remain in full force and effect so long as any amounts are due under the Agreement.
	SECTION 23.
	​

	(Borrower)(Please Print)
	​

	​
	​

	By: 
	​

	Date:
	​

​
​

​

​

SCHEDULE 1
LIST OF SUBSIDIARIES
[*]
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 1.1
COMMITMENTS
2018 TERM LOAN ADVANCES
​
	LENDER
	TRANCHE
	COMMITMENT
	ADVANCES OUTSTANDING AS OF SECOND AMENDMENT CLOSING DATE

	HERCULES CAPITAL, INC.
	2018 Term A Loan Advance
	$0
	$7,000,000

	HERCULES CAPITAL FUNDING TRUST 2018-1
	2018 Term A Loan Advance
	$0
	$13,000,000

	HERCULES CAPITAL FUNDING TRUST 2019-1
	2018 Term A Loan Advance
	$0
	$15,000,000

	TOTAL
	​
	$0
	$35,000,000

​
2021 TERM LOAN ADVANCES
​
	LENDER
	COMMITMENT

	HERCULES CAPITAL, INC.
	$100,000,000

	TOTAL COMMITMENTS
	$100,000,000

​
SECTION 24.
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 1A
INDEBTEDNESS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 1B
INVESTMENTS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 1C
LIENS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.3
CONSENTS, ETC.
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.5
ACTIONS BEFORE GOVERNMENTAL AUTHORITIES
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.8
TAX MATTERS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.9
INTELLECTUAL PROPERTY CLAIMS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.10
INTELLECTUAL PROPERTY
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.11
BORROWER PRODUCTS
​
[*]
​
​

Exhibit A to Amendment No. 2 to Loan and Security Agreement

​

SCHEDULE 5.14
CAPITALIZATION
​
Capitalization – see SEC Form 20-F published on 4 April 2016 or Dutch annual accounts
​
Subsidiaries – see Schedule 1

Exhibit A to Amendment No. 2 to Loan and Security Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]